Harrow Health (HROW) 10-K 12 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 11, 2015	Jun. 30, 2014
Document And Entity Information
Entity Registrant Name	Imprimis Pharmaceuticals, Inc.
Entity Central Index Key	1360214
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Entity Voluntary Filers	No
Entity Well-KnownSeasoned Issuer	No
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$47,000,000
Entity Common Stock, Shares Outstanding		9,342,935
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets
Cash and cash equivalents	$8,211,492	$15,579,309
Restricted short-term investments	150,264	50,097
Accounts receivable, net	81,322
Inventories	372,735
Prepaid expenses and other current assets	240,401	105,067
Total current assets	9,056,214	15,734,473
Intangible assets, net	610,994
Goodwill	331,621
Furniture and equipment, net	243,395	26,892
TOTAL ASSETS	10,242,224	15,761,365
Current liabilities
Accounts payable and accrued expenses	786,675	311,924
Accrued payroll and related liabilities	716,332	338,703
Customer deposits	1,683
Current portion of contingent acquisition obligations	31,466
Current portion of capital lease obligations	24,112
Total current liabilities	1,560,268	650,627
Capital lease obligations, net of current portion	18,968
Accrued expenses, net of current portion	29,658
Contingent acquisition obligations	483,156
TOTAL LIABILITIES	2,092,050	650,627
Commitments and contingencies
STOCKHOLDERS' EQUITY
Common stock, $0.001 par value, 90,000,000 shares authorized, 9,258,231 and 8,970,364 shares issued and outstanding at December 31, 2014 and 2013, respectively	9,258	8,970
Additional paid-in capital	50,006,411	46,849,160
Accumulated deficit	-41,865,495	-31,747,392
TOTAL STOCKHOLDERS' EQUITY	8,150,174	15,110,738
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$10,242,224	$15,761,365

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	90,000,000	90,000,000
Common stock, shares issued	9,258,231	8,970,364
Common stock, shares outstanding	9,258,231	8,970,364

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Revenues:
Sales, net	$1,652,386
License revenues	7,860	10,000
Total revenues	1,660,246	10,000
Cost of sales	-1,092,839
Gross profit	567,407	10,000
Operating expenses:
Selling and marketing	2,390,180	85,890
General and administrative	8,087,316	5,994,907
Research and development	236,660	1,616,082
Total operating expenses	10,714,156	7,696,879
Loss from operations	-10,146,749	-7,686,879
Other income (expense):
Interest expense	-3,800
Interest income	32,446	43,755
Total other income, net	28,646	43,755
Net loss	($10,118,103)	($7,643,124)
Basic and diluted net loss per share of common stock	($1.11)	($0.88)
Weighted average number of shares of common stock outstanding, basic and diluted	9,132,989	8,656,822

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2012	$6,772	$34,093,933	($24,104,268)	$9,996,437
Balance, share at Dec. 31, 2012	6,772,066
Issuance of common stock related to consulting agreements	40	282,957		282,997
Issuance of common stock related to consulting agreements, shares	40,000
Exercise of stock options, shares	219
Cancelled common stock at $5.25 per share related to reverse stock split, February 2013		-191		-191
Cancelled common stock at $5.25 per share related to reverse stock split, February 2013, shares	-35
Public offering of common stock at $5.25 per share, net of costs of $596,281, in February and March 2013	2,116	9,454,435		9,456,551
Public offering of common stock at $5.25 per share, net of costs of $596,281, in February and March 2013, shares	2,116,000
Issuance of common stock upon vesting of RSUs	40	-40
Issuance of common stock upon vesting of RSUs, shares	40,000
Stock-based compensation	2	3,018,066		3,018,068
Stock-based compensation, shares	2,114
Net loss			-7,643,124	-7,643,124
Balance at Dec. 31, 2013	8,970	46,849,160	-31,747,392	15,110,738
Balance, share at Dec. 31, 2013	8,970,364
Exercise of stock options, net of tax withholding	227	583,584		583,811
Exercise of stock options, net of tax withholding, shares	227,216			227,216
Stock-based compensation		2,469,810		2,469,810
Issuance of common stock related to consulting agreements	4	29,156		29,160
Issuance of common stock related to consulting agreements, shares	4,000
Issuance of common stock upon vesting of RSUs net of tax withholding	2	-13,111		-13,109
Issuance of common stock upon vesting of RSUs net of tax withholding , shares	1,954			1,954
Exercise of warrants	48	37,819		37,867
Exercise of warrants , shares	47,829
Common stock issued in settlement of contract dispute	7	49,993		50,000
Common stock issued in settlement of contract dispute, shares	6,868
Net loss			-10,118,103	-10,118,103
Balance at Dec. 31, 2014	$9,258	$50,006,411	($41,865,495)	$8,150,174
Balance, share at Dec. 31, 2014	9,258,231

Consolidated_Statements_of_Sto1

Consolidated Statements of Stockholders' Equity (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2013
Statement of Stockholders' Equity [Abstract]
Issuance of common stock for public offering price per share	$5.25
Cancelled common stock price per share	$5.25

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	($10,118,103)	($7,643,124)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of furniture and equipment	37,343	5,659
Amortization of intangible assets	48,006
Stock-based compensation and payments	2,614,619	3,134,973
Changes in assets and liabilities, net of effects from acquisitions:
Accounts receivable	-22,902
Inventories	-159,545
Prepaid expenses and other current assets	-131,727	-16,964
Accounts payable and accrued expenses	345,360	-239,800
Accrued payroll and related liabilities	342,154	320,312
Customer deposits	-10,633
NET CASH USED IN OPERATING ACTIVITIES	-7,055,428	-4,438,944
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of restricted short-term investments	-100,167	-50,000
Purchase of Pharmacy Creations, LLC, net of cash and advances	-636,374
Purchases of furniture and equipment	-173,986	-20,003
NET CASH USED IN INVESTING ACTIVITIES	-910,527	-70,003
CASH FLOWS FROM FINANCING ACTIVITIES
Cancelled common stock	-13,109	-191
Payments on capital lease obligations	-10,431
Net proceeds from exercise of warrants and stock options	621,678
Proceeds from issuance of common stock and warrants for cash, net of offering costs		10,052,832
NET CASH PROVIDED BY FINANCING ACTIVITIES	598,138	10,052,641
NET CHANGE IN CASH AND CASH EQUIVALENTS	-7,367,817	5,543,694
CASH AND CASH EQUIVALENTS, beginning of period	15,579,309	10,035,615
CASH AND CASH EQUIVALENTS, end of period	8,211,492	15,579,309
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes	800	1,600
Cash paid for interest	3,800
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Issuance of and adjustment to common stock and warrants to consulting firms for prepaid consulting fees		319,786
Reclassification of deferred offering costs in connection with equity offering		596,281
Issuance of common stock for consulting services included in accounts payable and accrued expenses		139,444
Purchase of furniture and equipment with a capital lease	$35,350

Organization

Organization	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	NOTE 1. ORGANIZATION
	Imprimis Pharmaceuticals, Inc. (together with its subsidiaries, unless the context indicates or otherwise requires, the “Company” or “Imprimis”) is a pharmaceutical company focused on developing and commercializing innovative and high quality proprietary compounded drug therapies and making these therapies available to physicians and patients at accessible prices. The Company owns, markets and sells a portfolio of proprietary combination formulations in ophthalmology and urology that it believes may offer competitive advantages and serve unmet needs in the marketplace. The Company’s ophthalmology formulation portfolio, led by its Dropless Therapy™ and LessDrops™ formulations, serves the multi-billion dollar eye drop market and is designed to address patient compliance issues and provide other medical and economic benefits to physicians and patients. The Company recently launched its urology business, headed by its Defeat IC™ campaign, which currently includes a patented compounded formulation for patients suffering from interstitial cystitis. The Company is also developing additional complementary proprietary compounded formulations to add to its ophthalmology and urology formulation portfolios. The Company makes, dispenses and sells its proprietary compounded formulations, as well as other non-proprietary products, through its wholly owned compounding pharmacies.
	On April 1, 2014, the Company acquired Pharmacy Creations, LLC (“PC”), a New Jersey based compounding pharmacy and on January 1, 2015, the Company acquired South Coast Specialty Compounding, Inc. D/B/A Park Compounding (“Park”), a California based compounding pharmacy (see Note 16). Effective with the acquisition of PC, the Company commenced sales and marketing efforts for Imprimis’ portfolio of proprietary and non-proprietary compounded drug formulations.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of Presentation
	On February 28, 2012, the Company effected a one-for-eight reverse stock split and on February 7, 2013, the Company effected a one-for-five reverse stock split. All share and per share amounts in these consolidated financial statements and notes reflect the effects of these reverse stock splits.
	Imprimis has prepared the accompanying consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.
	Business Combinations
	The Company accounts for business combinations by recognizing the assets acquired, liabilities assumed, contractual contingencies, and contingent consideration at their fair values on the acquisition date. The purchase price allocation process requires management to make significant estimates and assumptions at the acquisition date, especially with respect to intangible assets, estimated contingent consideration payments and pre-acquisition contingencies. Examples of critical estimates in valuing certain of the intangible assets the Company has acquired or may acquire in the future include but are not limited to:
		●	future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed technologies and patents; and
		●	discount rates utilized in valuation estimates.
	Unanticipated events and circumstances may occur that may affect the accuracy or validity of such assumptions, and estimates compared to actual results. Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date, including changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets, will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have a material effect on the consolidated financial position, statements of operations, or cash flows in the period of the change in the estimate.
	Research and Development
	The Company expenses all costs related to research and development as they are incurred. Research and development expenses consist of expenses incurred in performing research and development activities, including salaries and benefits, other overhead expenses, and costs related to clinical trials, contract services and outsourced contracts.
	Intellectual Property
	The costs of acquiring intellectual property rights to be used in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where the Company has identified an alternative future use for the acquired rights. No costs associated with acquiring intellectual property rights have been capitalized to date, although the Company may begin to capitalize certain costs associated with intellectual property rights beginning in the fiscal year 2015. Costs of maintaining intellectual property rights are expensed as incurred.
	Revenue Recognition and Deferred Revenue
	The Company recognizes revenues when all of the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. The Company began generating revenues upon the acquisition of PC in the second quarter of 2014, which include sales of certain of the Company’s proprietary compounded drug formulations and certain non-proprietary formulations.
	Product Revenues
	Determination of criteria (3) and (4) is based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Estimated returns and allowances and other adjustments are provided for in the same period during which the related sales are recorded. The Company will defer any revenue received for a product that has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered and no refund will be required.
	License Revenues
	License arrangements may consist of non-refundable upfront license fees, data transfer fees, research reimbursement payments, exclusive license rights to patented or patent pending compounds, technology access fees, and various performance or sales milestones. These arrangements can be multiple element arrangements.
	Non-refundable fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on the part of the Company, are recognized as revenue when the license term commences and the licensed data, technology, compounded drug preparation and/or other deliverable is delivered. Such deliverables may include physical quantities of compounded drug preparations, design of the compounded drug preparations and structure-activity relationships, the conceptual framework and mechanism of action, and rights to the patents or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable fees if it has continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee and that are separate and independent of the Company’s performance under the other elements of the arrangement. In addition, if the Company’s continued involvement is required, through research and development services that are related to its proprietary know-how and expertise of the delivered technology or can only be performed by the Company, then such non-refundable fees are deferred and recognized over the period of continuing involvement. Guaranteed minimum annual royalties are recognized on a straight-line basis over the applicable term.
	Cost of Sales
	Cost of sales includes direct and indirect costs to manufacture formulations and other products sold, including active pharmaceutical ingredients, personnel costs, packaging, storage, royalties (see Note 14), shipping and handling costs and the write-off of obsolete inventory.
	Income Taxes
	As part of the process of preparing the Company’s consolidated financial statements, the Company must estimate the actual current tax liabilities and assess temporary differences resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within the balance sheet. The Company must assess the likelihood that the deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, a valuation allowance must be established. To the extent the Company establishes a valuation allowance or increase or decrease this allowance in a period, the impact will be included in income tax expense in the statement of operations.
	The Company accounts for income taxes under the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740, “Income Taxes”, or ASC 740. As of December 31, 2014, there were no unrecognized tax benefits included in the consolidated balance sheet that would, if recognized, affect the effective tax rate. The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties in its consolidated balance sheets at December 31, 2014 and 2013, and has not recognized interest and/or penalties in the consolidated statements of operations for the years ended December 31, 2014 and 2013. The Company is subject to taxation in the United States and California. The Company’s tax years since 2000 are subject to examination by the federal and state tax authorities due to the carryforward of unutilized net operating losses.
	Cash and Cash Equivalents
	Cash equivalents include short-term, highly liquid investments with maturities of three months or less at the time of acquisition.
	Concentrations of Credit Risk
	The Company places its cash with financial institutions deemed by management to be of high credit quality. The Federal Deposit Insurance Corporation (“FDIC”) provides basic deposit coverage with limits up to $250,000 per owner. At December 31, 2014, the Company had approximately $7.7 million in cash deposits in excess of FDIC limits.
	Accounts Receivable
	The balance in accounts receivable consists of revenue amounts the Company has invoiced and recognized, but for which payment has not been received. Accounts receivable are presented net of an allowance for doubtful accounts in the amount of $3,957 as of December 31, 2014.
	Inventories
	Inventories are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. The Company evaluates the carrying value of inventories on a regular basis, based on the price expected to be obtained for products in their respective markets compared with historical cost. Write-downs of inventories are considered to be permanent reductions in the cost basis of inventories.
	The Company also regularly evaluates its inventories for excess quantities and obsolescence (expiration), taking into account such factors as historical and anticipated future sales or use in production compared to quantities on hand and the remaining shelf life of products and active pharmaceutical ingredients on hand. The Company establishes reserves for excess and obsolete inventories as required based on its analyses.
	Furniture and Equipment
	Furniture and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization is calculated using the straight-line method over the estimated useful life of the asset. Leasehold improvements and capital lease equipment are amortized over the estimated useful life or remaining lease term, whichever is shorter. Computer software and hardware and furniture and equipment are depreciated over three to five years.
	Goodwill and Intangible Assets
	The Company reviews its goodwill and indefinite-lived intangible assets for impairment as of January 1 of each year and when an event or a change in circumstances indicates the fair value of a reporting unit may be below its carrying amount. Events or changes in circumstances considered as impairment indicators include but are not limited to the following:
		●	significant underperformance of the Company’s business relative to expected operating results;
		●	significant adverse economic and industry trends;
		●	significant decline in the Company’s market capitalization for an extended period of time relative to net book value; and
		●	expectations that a reporting unit will be sold or otherwise disposed.
	The goodwill impairment test consists of a two-step process as follows:
	Step 1. The Company compares the fair value of each reporting unit to its carrying amount, including the existing goodwill. The fair value of each reporting unit is determined using a discounted cash flow valuation analysis. The carrying value of each reporting unit is determined by specifically identifying and allocating the assets and liabilities to each reporting unit based on headcount, relative revenues, or other methods as deemed appropriate by management. If the carrying amount of a reporting unit exceeds its fair value, an indication exists that the reporting unit’s goodwill may be impaired and the Company then performs the second step of the impairment test. If the fair value of a reporting unit exceeds its carrying amount, no further analysis is required.
	Step 2. If further analysis is required, the Company compares the implied fair value of the reporting unit’s goodwill, determined by allocating the reporting unit’s fair value to all of its assets and its liabilities in a manner similar to a purchase price allocation, to its carrying amount. If the carrying amount of the reporting unit’s goodwill exceeds its fair value, an impairment loss will be recognized in an amount equal to the excess.
	Impairment of Long-Lived Assets
	Long-lived assets, such as furniture and equipment and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the consolidated balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposal group classified as held-for-sale would be presented separately in the appropriate asset and liability sections of the consolidated balance sheet, if material.
	During the years ended December 31, 2014 and 2013, the Company did not recognize any impairment of its long-lived assets.
	Deferred Rent
	The Company accounts for rent expense related to its operating leases by determining total minimum rent payments on the leases over their respective periods and recognizing the rent expense on a straight-line basis. The difference between the actual amount paid and the amount recorded as rent expense in each fiscal year and interim periods within each fiscal year is recorded as an adjustment to deferred rent.
	Fair Value Measurements
	Fair value measurements are determined based on the assumptions that market participants would use in pricing an asset or liability. GAAP establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The established fair value hierarchy prioritizes the use of inputs used in valuation methodologies into the following three levels:
	●	Level 1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure fair value whenever available.
	●	Level 2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
	●	Level 3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entity’s own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level 3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method.
	At December 31, 2014 and 2013, the Company did not have any financial assets or liabilities that are measured on a recurring basis. At December 31, 2014 and 2013, the Company’s financial instruments included cash and cash equivalents, restricted short-term investments, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, customer deposits, and capital leases. The carrying amount of these financial instruments, except for the restricted short-term investments and the capital leases, approximates fair value due to the short-term maturities of these instruments. The Company’s restricted short-term investments are carried at amortized cost, which approximates fair value. Based on borrowing rates currently available to the Company, the carrying values of the capital leases approximate their respective fair values.
	Stock-Based Compensation
	All stock-based payments to employees, directors and consultants, including grants of stock options, warrants, restricted stock units (“RSUs”) and restricted stock, are recognized in the consolidated financial statements based upon their fair values. The Company uses the Black-Scholes-Merton option pricing model and Monte Carlo Simulation to estimate the fair value of stock-based awards. The estimated fair value is determined at the date of grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates.
	The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the Financial Accounting Standards Board (the “FASB”) guidance. As such, the value of the applicable stock-based compensation is periodically remeasured and income or expense is recognized during the vesting terms of the equity instrument. The measurement date for the estimated fair value of the equity instruments issued is the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the estimated fair value of the equity instrument is primarily recognized over the term of the consulting agreement. In accordance with FASB guidance, an asset acquired in exchange for the issuance of fully vested, nonforfeitable equity instruments should not be presented or classified as an offset to equity on the grantor’s balance sheet once the equity instrument is granted for accounting purposes. Accordingly, the Company records the estimated fair value of nonforfeitable equity instruments issued for future consulting services as prepaid expenses in its consolidated balance sheets.
	Basic and Diluted Net Loss per Common Share
	Basic net loss per common share is computed by dividing net loss attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as stock options and warrants, outstanding during the period.
	Basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Common stock equivalents (using the treasury stock or, “if converted” method) from stock options, RSUs and warrants were 3,024,217 and 3,539,800 at December 31, 2014 and 2013, respectively, and are excluded from the calculation of diluted net loss per share for all periods presented because the effect is anti-dilutive. Common stock equivalents at December 31, 2014 include 27,218 shares of common stock underlying RSUs, awarded to directors that have vested, but the issuance and delivery of these shares are deferred until the director resigns.
	The following table shows the computation of basic and diluted net loss per share of common stock for the years ended December 31, 2014 and 2013:
			For the			For the
		Year Ended			Year Ended
		31-Dec-14			31-Dec-13
Numerator – net loss		$	(10,118,103	)	$	(7,643,124	)
Denominator – weighted average number of shares outstanding, basic and diluted			9,132,989			8,656,822
Net loss per share, basic and diluted		$	(1.11	)	$	(0.88	)
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets, and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management are, among others, allowance for doubtful accounts, realizability of inventories, valuation of deferred taxes, goodwill and intangible assets, recoverability of long-lived assets and goodwill, valuation of contingent acquisition obligations, and valuation of stock-based compensation issued to employees and non-employees. Actual results could differ from those estimates.
Reclassifications
Certain prior period items and amounts have been reclassified to conform to the classifications used to prepare the consolidated financial statements for the year ended December 31, 2014. The Company has classified in these financial statements certain expenses as selling and marketing, whereas in prior periods certain of these expenses were included in an expense line item titled selling, general and administrative in the consolidated statements of operations. These reclassifications had no material impact on the Company’s financial position, results of operations, or cash flows as previously reported.
Recently Adopted Accounting Pronouncements
In June 2014, the FASB issued an Accounting Standards Update (“ASU”) No. 2014-10, “Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities”. The amendments in this update remove the definition of a development stage entity from ASC Topic 915, “Development Stage Entities”, thereby removing from GAAP the distinction between development stage entities and other reporting entities. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of operations, cash flows, and stockholder’s equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. These amendments are effective for annual reporting periods beginning after December 15, 2014, with early application of the amendments permitted. The Company’s pharmacy operations commenced on April 1, 2014. This change in the nature of the Company’s operations included the recognition of operating revenues; as a result, the Company is no longer defined as a development stage company for reporting dates beginning April 1, 2014. With the change in the Company’s operations, its revenue recognition and its immediate adoption of ASU No. 2014-10, the Company no longer presents or discloses any information required under ASC Topic 915.
Recently Issued Accounting Pronouncements
In August 2014, the FASB issued new accounting guidance which defines management’s responsibility to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. This guidance will be effective for annual periods ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. The Company is currently evaluating the new guidance and has not determined the impact this standard may have on its consolidated financial statements.
In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”). The objective of ASU 2014-19 is to establish a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most of the existing revenue recognition guidance, including industry-specific guidance. The core principle of ASU 2014-09 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In applying the new guidance, an entity will (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the contract’s performance obligations; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 applies to all contracts with customers except those that are within the scope of other topics in the FASB ASC. The new guidance is effective for annual reporting periods, including interim periods within those periods, beginning after December 15, 2016 for public companies. Early adoption is not permitted. The Company is currently evaluating the new guidance and has not determined the impact this standard may have on its consolidated financial statements.

Acquisition_Pharmacy_Creations

Acquisition - Pharmacy Creations, LLC	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Acquisition - Pharmacy Creations, LLC	NOTE 3. ACQUISITION – PHARMACY CREATIONS, LLC
	On April 1, 2014, the Company acquired all of the outstanding membership interests of PC (the “PC Acquisition”) from J. Scott Karolchyk and Bernard Covalesky (the “PC Sellers”), such that PC became a wholly-owned subsidiary of the Company. The acquisition of PC permits the Company to make and distribute its patent-pending proprietary drug formulations and other pharmaceutical preparations.
	The transaction has been accounted for as a business combination and the financial results of PC have been included in the Company’s consolidated financial statements for the period subsequent to its acquisition.
	The estimated acquisition date fair value of consideration transferred, assets acquired and liabilities assumed for PC are presented below and represent the Company’s best estimates.
	Fair Value of Consideration Transferred
	At the closing of the PC Acquisition, the Company paid to the PC Sellers an aggregate cash purchase price of $600,000. In addition, the PC Sellers are entitled to receive additional contingent consideration upon the satisfaction of certain conditions, as follows:
		●	A contingent cash payment of $50,000, payable if PC earns revenues of over $3,500,000 for the 12 month period ending March 31, 2015.
		●	A contingent stock payment of up to an aggregate of 215,190 shares of the Company’s common stock, issuable only if the following revenue milestones are met:
		●	if PC earns revenue of over $7,500,000 during the 12 month period ending March 31, 2016, all 215,190 shares;
		●	if PC earns revenue of between $3,500,000 and $7,500,000 during the 12 month period ending March 31, 2016, an aggregate of that number of shares of Imprimis common stock equal to the amount that such revenue exceeds $3,500,000 divided by 18.5882, rounded down to the lower whole number (not to exceed 215,190 shares).
	Although management estimates that certain of the contingent consideration will be paid, it has applied a discount rate to the contingent consideration amounts in determining fair value to represent the risk of these payments not being made. The total acquisition date fair value of the consideration transferred and to be transferred is estimated at approximately $1.1 million, as follows:
	Cash payment to the PC Sellers at closing		$	600,000
	Contingent common stock issuance to the PC Sellers			483,156
	Contingent cash consideration to the PC Sellers			31,466
	Total acquisition date fair value		$	1,114,622
	A $514,622 liability was recognized for the estimated acquisition date fair value of the future contingent common stock and cash payments and is included in the contingent acquisition obligations in the accompanying consolidated balance sheet at December 31, 2014.
	Allocation of Consideration Transferred
	The identifiable assets acquired and liabilities assumed were recognized and measured as of the acquisition date based on their estimated fair values as of April 1, 2014, the acquisition date. The excess of the acquisition date fair value of consideration transferred over the estimated fair value of the net tangible assets and intangible assets acquired was recorded as goodwill.
	The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date.
	Cash and cash equivalents		$	4,982
	Accounts receivable			58,420
	Prepaid expenses and other assets			30,256
	Inventory			213,190
	Property and equipment			44,510
	Intangible assets			659,000
	Total identifiable assets acquired			1,010,358
	Accounts payable and accrued liabilities			120,049
	Other liabilities			107,308
	Total liabilities assumed			227,357
	Total identifiable assets less liabilities assumed			783,001
	Goodwill			331,621
	Net assets acquired		$	1,114,622
	Results of Operations
	The amount of revenues and operating loss of PC included in the Company’s consolidated statement of operations from the acquisition date through the period ended December 31, 2014 are as follows:
	Total revenues		$	1,652,386
	Operating loss		$	(662,969	)
	Pro Forma Financial Information
	The following table presents the Company’s unaudited pro forma results (including PC) for the years ended December 31, 2014 and 2013 as though the companies had been combined as of the beginning of each of the periods presented. The pro forma information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisition had taken place at the beginning of each period presented, nor is it indicative of results of operations which may occur in the future. The unaudited pro forma results presented include amortization charges for intangible assets and eliminations of intercompany transactions.
			For the			For the
			Year Ended			Year Ended
			31-Dec-14			31-Dec-13
	Total revenues		$	2,282,681		$	2,866,575
	Net loss		$	(10,048,380	)	$	(7,084,014	)
	The Company did not incur material acquisition expenses related to the PC Acquisition.
	Intangible Assets
	Management engaged a third-party valuation firm to assist in the determination of the fair value of the acquired intangible assets of PC. In determining the fair value of the intangible assets, the Company considered, among other factors, the best use of acquired assets, analyses of historical financial performance of PC and estimates of future performance of PC. The fair values of the identified intangible assets related to PC’s customer relationships, trade name, non-competition covenant, and state pharmacy licenses. The fair value of customer relationships and the non-competition covenant were calculated using the income approach. The fair value of the trade name and state pharmacy licenses were calculated using the cost approach. The following table sets forth the components of identified intangible assets associated with the PC acquisition and their estimated useful lives.
			Fair Value			Useful Life
	Customer relationships		$	596,000		10 - 15 years
	Trade name			5,000		5 years
	Non-competition covenant			50,000		4 years
	State pharmacy licenses			8,000		25 years
			$	659,000
	The Company determined the useful lives of intangible assets based on the expected future cash flows and contractual lives associated with the respective asset. Trade names represent the fair value of the brand and name recognition associated with the marketing of PC’s formulations and services. Customer relationships represent the expected benefit from customer contracts that, at the date of acquisition, were reasonably anticipated to continue given the history and operating practices of PC. The non-competition covenant represents the contractual period and expected degree of adverse economic impact that would exist in its absence. Licenses represent eight state pharmacy licenses PC held at the date of acquisition.
	Goodwill
	Of the total estimated purchase price, $331,621 was allocated to goodwill and is attributable to expected synergies between the combined companies, including access for the Company to fulfill prescriptions with its patent-pending proprietary drug formulations through PC’s market channels and assembled workforce. Goodwill represents the excess of the purchase price of the acquired business over the estimated fair value of the underlying net tangible and intangible assets acquired. Goodwill resulting from the PC Acquisition will be tested for impairment at least annually and more frequently if certain indicators of impairment are present. In the event the Company determines that the value of goodwill has become impaired, it will incur an accounting charge for the amount of the impairment during the fiscal quarter in which the determination is made. None of the goodwill is expected to be deductible for income tax purposes.

Restricted_ShortTerm_Investmen

Restricted Short-Term Investment	12 Months Ended
	Dec. 31, 2014
Restricted Short-term Investment
Restricted Short-Term Investment	NOTE 4. RESTRICTED SHORT-TERM INVESTMENTS
	The restricted short-term investments at December 31, 2014 consist of certificate of deposits, which are classified as held-to-maturity. At December 31, 2014, the restricted short-term investments were recorded at amortized cost which approximates fair value.
	At December 31, 2014, the certificate of deposits of $150,264 were classified as a current asset. The certificates of deposit are required as collateral under the Company’s corporate credit card agreement and office lease agreement and automatically renew every twelve months.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventories	NOTE 5. INVENTORIES
	Inventories are comprised of over-the-counter retail pharmacy products, commercial pharmaceutical products, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of December 31, 2014 was as follows:
		31-Dec-14
	Raw materials	$	146,300
	Work in progress		97,801
	Finished goods		128,634
	Total inventories	$	372,735

Prepaid_Expenses_and_Other_Cur

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	NOTE 6. PREPAID EXPENSES AND OTHER CURRENT ASSETS
	Prepaid expenses and other current assets consisted of the following:
		31-Dec-14		31-Dec-13
	Prepaid stock-based consulting expenses	$	-	$	26,649
	Prepaid rent		-		16,288
	Prepaid insurance		123,776		39,166
	Other prepaid expenses and deposits		116,625		22,964
	Total prepaid expenses and other current assets	$	240,401	$	105,067

Furniture_and_Equipment

Furniture and Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Furniture and Equipment	NOTE 7. FURNITURE AND EQUIPMENT
	Furniture and equipment consisted of the following:
		31-Dec-14			31-Dec-13
	Furniture and equipment, net:
	Computer software and hardware	$	52,576		$	24,536
	Furniture and equipment		154,215			10,449
	Lab and pharmacy equipment		61,868			-
	Leasehold improvements		20,172			-
			288,831			34,985
	Accumulated depreciation and amortization		(45,436	)		(8,093	)
		$	243,395		$	26,892
	The Company recorded depreciation and amortization expense of $37,343 and $5,659 during the years ended December 31, 2014 and 2013, respectively.

Intangible_Assets_and_Goodwill

Intangible Assets and Goodwill	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	NOTE 8. INTANGIBLE ASSETS AND GOODWILL
	The Company’s intangible assets at December 31, 2014 consisted of the following:
		Amortization
		periods				Accumulated			Net
		(in years)		Cost		amortization			carrying value
	Customer relationships	10-15 years		$	596,000	$	(36,740	)	$	559,260
	Trade name	5 years			5,000		(750	)		4,250
	Non-competition covenant	4 years			50,000		(9,375	)		40,625
	State pharmacy licenses	25 years			8,000		(1,141	)		6,859
				$	659,000	$	(48,006	)	$	610,994
	Amortization expense for intangible assets for the year ended December 31, 2014 was as follows:
		For the
		Year Ended
		31-Dec-14
	Customer relationships	$	36,740
	Trade name		750
	Non-competition covenant		9,375
	State pharmacy licenses		1,141
		$	48,006
	Estimated future amortization expense for the Company’s intangible assets at December 31, 2014 is as follows:
	Years ending December 31,
	2015	$	67,087
	2016		67,087
	2017		67,087
	2018		57,712
	2019		53,837
	Thereafter		298,184
		$	610,994
	The changes in the carrying value of the Company’s goodwill during the year ended December 31, 2014 were as follows:
	Balance at January 1, 2014	$	-
	PC Acquisition		331,621
	Balance at December 31, 2014	$	331,621

Accounts_Payable_and_Accrued_E

Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	NOTE 9. ACCOUNTS PAYABLE AND ACCRUED EXPENSES
	Accounts payable and accrued expenses consisted of the following:
			31-Dec-14			31-Dec-13
	Accounts payable		$	698,806		$	261,924
	Deferred rent			4,975			-
	Building lease liability(1)			73,552			-
	Other accrued expenses			39,000	-2		50,000
	Total accounts payable and accrued expenses			816,333			311,924
	Less: Current portion			(786,675	)		(311,924	)
	Non-current total accounts payable and accrued expenses		$	29,658		$	-
		-1	In September 2014, the Company relocated its primary operations to a 7,565 square foot office facility in San Diego, California. As of December 31, 2014, the Company was marketing its previous office space (3,874 square feet) as a sublease through its remaining lease term. The Company recognized a loss of approximately $117,000 during the year ended December 31, 2014, related to the estimated remaining lease liability, net of expected sublease income. The obligations were discounted based on current prevailing market rates. This loss is included in rent expense for the year ended December 31, 2014 (see Note 14).
		-2	The amount consists of a $39,000 stock-based compensation accrual at December 31, 2014 for stock options to be granted for services performed. The stock-based compensation expense related to restricted common stock issuances and accruals was $39,000 and $143,553 during the years ended December 31, 2014 and 2013, respectively.

Debt

Debt	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt	NOTE 10. DEBT
	PC entered into a working capital line of credit agreement with a financial institution on March 21, 2008 and subsequently renewed the agreement on September 6, 2013. The line of credit agreement allowed PC to borrow up to $75,000 and was secured by a first security interest on all of PC’s business assets. The line of credit agreement was terminated following the Company’s acquisition of PC, and no amounts were borrowed, paid or outstanding during the period ended December 31, 2014 following the Company’s acquisition of PC.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Stockholders' Equity	NOTE 11. STOCKHOLDERS’ EQUITY
	Common Stock
	Issuances During the Year Ended December 31, 2013
	On February 7, 2013, after the effectiveness of the registration statement on Form S-1 filed in connection with the Public Offering (as defined below), the Company effected a one-for-five reverse stock split of its common stock and on February 8, 2013, the Company’s common stock began trading on The NASDAQ Capital Market on a split-adjusted basis. On September 10, 2014, the Company decreased the number of authorized shares of its capital stock to 95,000,000, and the number of authorized shares of its common stock to 90,000,000.
	On February 13, 2013, the Company closed a public offering of its common stock (the “Public Offering”) and issued an aggregate of 1,840,000 shares of its common stock at a per share price to the public of $5.25, and received net proceeds of $8,140,435, after deducting underwriter fees and commissions and other offering expenses. The underwriters also exercised their option to purchase an additional 276,000 shares of common stock from the Company at $5.25 per share to cover over-allotments on March 14, 2013. Net cash proceeds from the exercise of the over-allotment option were $1,316,116. As contemplated by the underwriting agreement entered into with MDB Capital Group, LLC, the lead underwriter for the Public Offering, at the closing of the Public Offering and the over-allotment exercise, the lead underwriters received warrants (the “Underwriter Warrants”) to purchase up to an aggregate of 179,860 shares, or 8.5% of the number of shares sold in the Public Offering (including 8.5% of shares sold pursuant to the exercise of the over-allotment option). The Underwriter Warrants are exercisable at $5.25 per share (100% of the price to the public of the common stock sold in the Public Offering), commencing on the closing date of the Public Offering and expire five years from the closing date of the Public Offering.
	In February and March 2013, the Company made payments totaling $191 in connection with cancelled, fractional share amounts of common stock (35 common stock share equivalents) in connection with the one-for-five reverse stock split effected February 7, 2013.
	In June 2013, the Company issued 40,000 shares of common stock to Mark Baum, the Company’s Chief Executive Officer and a director, related to the vesting of RSUs.
	In September 2013, the Company issued 2,114 restricted shares of common stock to a consultant, valued at $10,750, in consideration for consulting services provided during the year ended December 31, 2013. The fair value of the shares of common stock issued was recorded as stock-based compensation during the year ended December 31, 2013.
	During the year ended December 31, 2013, the Company issued 40,000 restricted shares of common stock to Dr. Robert Kammer, a director and former consultant, valued at $282,997, in consideration for consulting services provided during the years ended December 31, 2013 and 2012.
	During the year ended December 31, 2013, the Company issued a total of 219 shares of common stock as a result of stock option exercises. The Company received no cash proceeds for the issuance of such shares upon the exercise pursuant to cashless exercise provisions of stock options to purchase 1,030 shares of common stock with an exercise price of $4.00 per share.
	Issuances During the Year Ended December 31, 2014
	In April 2014, the Company issued 6,868 shares of restricted common stock, valued at $50,000, in connection with the resolution of a contract dispute.
	In October 2014, the Company issued 4,000 shares of restricted common stock to a consultant, valued at $29,160 in consideration for consulting services provided. The fair value of the shares of common stock issued was recorded as stock-based compensation during the year ended December 31, 2014.
	During the year ended December 31, 2014, the Company issued a total of 227,216 shares of common stock as a result of stock option exercises. Of these, the Company received net cash proceeds of $583,811 for the issuance of 160,777 shares of common stock upon the exercise of stock options to purchase the same number of shares of common stock with exercise prices ranging from $3.68 to $4.00 and the Company received no cash proceeds for the issuance of 66,439 shares of common stock upon the exercise pursuant to cashless exercise provisions of stock options to purchase 146,652 shares of common stock with exercise prices ranging from $3.60 to $6.00 per share.
	During the year ended December 31, 2014, the Company issued 1,954 shares of common stock to employees related to the vesting of RSUs. In connection with these common stock issuances, the Company withheld 1,518 shares of common stock for payroll tax withholdings totaling $13,109.
	During the year ended December 31, 2014, the Company issued a total of 47,829 shares of common stock as a result of warrant exercises. Of these, the Company received gross cash proceeds of $37,867 for the issuance of 6,391 shares of common stock upon the exercise of warrants to purchase the same number of shares of common stock with an exercise price of $5.925 and the Company received no cash proceeds for the issuance of 41,438 shares of common stock upon the exercise pursuant to cashless exercise provisions of warrants to purchase 123,715 shares of common stock with an exercise price of $5.25 per share.
	During the year ended December 31, 2014, 27,218 shares of the Company’s common stock underlying RSUs issued to directors vested, but the issuance and delivery of these shares are deferred until the respective director resigns.
	Preferred Stock
	At December 31, 2014 and 2013, the Company had 5,000,000 shares of preferred stock, $0.001 par value, authorized and no shares of preferred stock issued and outstanding.
	Stock Option Plan
	On September 17, 2007, the Company’s Board of Directors and stockholders adopted the Company’s 2007 Incentive Stock and Awards Plan, which was subsequently amended on November 5, 2008, February 26, 2012, July 18, 2012, May 2, 2013 and September 27, 2013 (as amended, the “Plan”). As of December 31, 2014, the Plan provides for the issuance of a maximum of 5,000,000 shares of the Company’s common stock. The purpose of the Plan is to provide an incentive to attract and retain directors, officers, consultants, advisors and employees whose services are considered valuable, to encourage a sense of proprietorship and to stimulate an active interest of such persons in the Company’s development and financial success. Under the Plan, the Company is authorized to issue incentive stock options intended to qualify under Section 422 of the Internal Revenue Code, non-qualified stock options, RSUs and restricted stock. The Plan is administered by the Compensation Committee of the Company’s Board of Directors. The Company had 2,366,369 shares available for future issuances under the Plan at December 31, 2014.
	Stock Options
	A summary of the stock option activity under the Plan for the year ended December 31, 2014 is as follows:
			Number of shares				Weighted Avg. Exercise Price				Weighted Avg. Remaining Contractual Life				Aggregate Intrinsic Value
	Options outstanding - January 1, 2014			1,328,790			$	5.31
	Options granted			245,886			$	6.35
	Options exercised			(307,429	)		$	3.9
	Options cancelled/forfeit			(238,007	)		$	6.68
	Options outstanding - December 31, 2014			1,029,240			$	5.74				6.05			$	2,351,174
	Options exercisable			728,585			$	5.25				4.97			$	2,080,594
	Options vested and expected to vest			999,175			$	5.7				5.98			$	2,319,475
	The aggregate intrinsic value in the table above represents the total pre-tax amount of the proceeds, net of exercise price, which would have been received by option holders if all option holders had exercised and immediately sold all options with an exercise price lower than the market price on December 31, 2014, based on the closing price of the Company’s common stock of $7.50 on that date. The aggregate intrinsic value of stock options exercised during the year ended December 31, 2014 was approximately $1,161,000.
	During fiscal years 2014 and 2013, the Company granted stock options to certain employees, directors and consultants. The stock options were granted with an exercise price equal to the current market price of the Company’s common stock, as reported by the securities exchange or quotation system on which the common stock was then listed or quoted, at the grant date and have contractual terms ranging from three to 10 years. Vesting terms for options granted in fiscal years 2014 and 2013 to employees, directors and consultants typically included one of the following vesting schedules: 25% or 33% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% or 67%, respectively, of the shares subject to the option vest and become exercisable in equal quarterly installments thereafter over two or three years, respectively; quarterly vesting over a three year period; or monthly, quarterly or 100% vesting associated with the provision or completion of services provided under contracts with consultants. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plan) and in the event of certain modifications to the option award agreement.
	The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model. Prior to April 1, 2013, expected volatilities were based on historical volatility of the Company’s common stock and other factors. Following April 1, 2013, the expected volatility is based on the historical volatilities of the common stock of comparable publicly traded companies based on the Company’s belief that it has significantly changed its business operations and focus as of such date and as a result, it has limited relevant historical data regarding the volatility of its stock price on which to base a meaningful estimate of expected volatility. The expected term of options granted was determined in accordance with the “simplified approach” as the Company has limited, relevant, historical data on employee exercises and post-vesting employment termination behavior. The expected risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates. For option grants to employees and directors, the Company assigns a forfeiture factor of 10%. These factors could change in the future, which would affect the determination of stock-based compensation expense in future periods. Utilizing these assumptions, the fair value is determined at the date of grant.
	The table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees and directors:
			2014				2013
	Weighted-average fair value of options granted		$	5.22			$	6.04
	Expected terms (in years)			5.81 - 6.91				5.8-7
	Expected volatility			96 - 102%				102 - 123%
	Risk-free interest rate			1.37 - 1.65%				0.86 - 2.05%
	Dividend yield			-				-
	The table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to consultants:
			2014				2013
	Weighted-average fair value of options granted		$	6.15			$	5.63
	Expected terms (in years)			2.5 - 10				2.33 - 10
	Expected volatility			78 - 97%				80 - 366%
	Risk-free interest rate			0.10 - 1.68%				0.30 - 2.45%
	Dividend yield			-				-
	The following table summarizes information about stock options outstanding and exercisable at December 31, 2014:
					Options Outstanding												Options Exercisable
									Weighted
									Average				Weighted								Weighted
									Remaining				Average								Average
					Number				Contractual				Exercise				Number				Exercise
	Range of Exercise Prices				Outstanding				Life in Years				Price				Exercisable				Price
		$2.40 - $3.20				250,000				4.57			$	2.8				250,000			$	2.8
		$3.60 - $4.51				337,723				4.95			$	4.36				270,015			$	4.42
		$5.49 - $7.71				190,557				8.7			$	6.62				60,110			$	6.26
		$8.06 - $10.75				244,160				7.03			$	8.99				141,660			$	9.01
		$28.00 - $80.00				6,800				5.13			$	40.86				6,800			$	40.86
						1,029,240				6.05			$	5.74				728,585			$	5.25
	As of December 31, 2014, there was approximately $1,571,000 of total unrecognized compensation expense related to unvested stock options granted under the Plan. That expense is expected to be recognized over the weighted-average remaining vesting period of 2.1 years. The stock-based compensation for all stock options was $1,137,634 and $1,689,756 during the years ended December 31, 2014 and 2013, respectively.
	Restricted Stock Units
	RSU awards are granted subject to certain vesting requirements and other restrictions, including performance and market based vesting criteria. The grant-date fair value of the RSUs, which has been determined based upon the market value of the Company’s common stock on the grant date, is expensed over the vesting period of the RSUs. Unvested portions of RSUs issued to consultants are remeasured on an interim basis until vesting criteria is met. On May 2, 2013, the Board of Directors of the Company amended and restated the Plan to provide for the issuance of RSUs under the Plan.
Grants During the Year Ended December 31, 2013
On May 2, 2013, the Company granted 1,250,000 RSUs to its Chief Executive Officer, Mark Baum, pursuant to the Plan. Of these RSUs, 200,000 will vest on the third anniversary of the RSU grant date, subject to continued service to the Company and the remaining 1,050,000 RSUs will vest on the third anniversary of the RSU grant date, subject to the satisfaction of certain market-based and continued service conditions (the “Baum Performance Equity Award”). The market-based vesting criteria are separated into five equal tranches and require that the Company achieve and maintain certain stock price targets ranging from $10 per share to $30 per share during the three year period following the grant date. With certain limited exceptions, Mr. Baum must be employed with the Company on the third anniversary of the grant date in order for the Baum Performance Equity Award to vest. These market-based vesting conditions are further described below:
Tranche		Number of Shares		Target Share Price
Tranche 1		19.05% of the shares subject to the Baum Performance Equity Award		$10.00 or greater
Tranche 2		19.05% of the shares subject to the Baum Performance Equity Award		$15.00 or greater
Tranche 3		19.05% of the shares subject to the Baum Performance Equity Award		$20.00 or greater
Tranche 4		19.05% of the shares subject to the Baum Performance Equity Award		$25.00 or greater
Tranche 5		23.80% of the shares subject to the Baum Performance Equity Award		$30.00 or greater
For each respective tranche to vest the following conditions must be met: (i) the Company’s common stock must have an official closing price at or above the Target Share Price for the respective tranche (each such date, a “Trigger Date”); (ii) during the period that includes the Trigger Date and the immediately following 19 trading days (the “Measurement Period”), the arithmetic mean of the 20 closing prices of the Company’s common stock during the Measurement Period must be at or above the Target Share Price for such tranche; and (iii) with certain limited exceptions, Mr. Baum must be in continuous service with the Company through the third anniversary of the grant date. Any unvested RSUs under the Baum Performance Equity Award will be forfeited on the third anniversary of the grant date.
The earning and issuance of any shares under the Baum Performance Equity Award that would exceed the number of shares available for grant and/or the applicable annual per person grant limit for performance-based restricted stock units under the Plan as of the grant date of the Baum Performance Equity Award were subject to approval by the Board of Directors and the Company’s stockholders of increases tothe number of shares available for grant and the applicable annual per person grant limit for performance-based restricted stock units under the Plan. On May 2, 2013, the Board of Directors approved an amendment to the Plan to increase the number of shares available for grant from 2,400,000 to 5,000,000 shares and the applicable annual per person grant limit from 600,000 to 1,250,000 shares and on September 27, 2013, a majority of the Company’s stockholders approved the amendment to the Plan. The 450,000 RSUs subject to the Baum Performance Equity Award that were pending such approval were granted on that date.
Concurrent with the issuance of the 450,000 RSUs, Mr. Baum agreed to cancel 120,000 unvested RSUs previously granted to Mr. Baum in July 2012. As a result, the Company has treated the issuance of the 450,000 RSUs as a modification of the RSU grant made to Mr. Baum in July 2012. The total compensation cost to be recognized by the Company is equal to the original grant date fair value of the canceled RSUs plus any incremental cost calculated as the excess of the fair value of the 450,000 RSUs over the fair value of the canceled 120,000 RSUs on the modification date, which is September 27, 2013. The initial fair value of the 450,000 RSUs pursuant to the Baum Performance Equity Award granted to Mr. Baum was $189,000. No incremental cost was associated with the exchange of RSUs as the fair value prior to modification was more than after the modification. The 450,000 RSUs pursuant to the Baum Performance Equity Award were valued using a Monte Carlo Simulation with a three year life, 75% volatility and a risk free interest rate of 0.64%.
The initial fair value of the 200,000 RSUs and 600,000 RSUs pursuant to the Baum Performance Equity Award granted to Mr. Baum was $3,515,090. The 600,000 RSUs pursuant to the Baum Performance Equity Award were valued using a Monte Carlo Simulation with a three year life, 75% volatility and a risk free interest rate of 0.30%.
On May 24, 2013, the Company granted 100,000 RSUs to a consultant that were to vest based on the satisfaction of certain market-based conditions subject to the consultant’s continued service, among other things. These market-based vesting conditions are further described below:
Tranche		Number of Shares		Target Share Price
Tranche 1		20,000 shares		$10.00 or greater
Tranche 2		20,000 shares		$15.00 or greater
Tranche 3		20,000 shares		$20.00 or greater
Tranche 4		20,000 shares		$25.00 or greater
Tranche 5		20,000 shares		$30.00 or greater
For each respective tranche to vest the following conditions must have been met: (i) the Company’s common stock must have had an official closing price at or above the Target Share Price for the respective tranche (each such date a “Trigger Date”); (ii) during the period that included the Trigger Date and the immediately following 19 trading days (the “Measurement Period”), the arithmetic mean of the 20 closing prices during the Measurement Period have been at or above the Target Share Price for such tranche ((i) and (ii), the “Stock Price Conditions”); and (iii) with certain limited exceptions, 50% of the RSUs subject to a tranche would vest on the quarterly anniversary of the grant date following the satisfaction of the Stock Price Conditions with respect to that tranche, subject to the consultant being in continuous service with the Company on such quarterly anniversary and the remaining 50% would vest on the second anniversary of the grant date if (a) the Stock Price Conditions had been satisfied with respect to that tranche prior to the second anniversary of the grant date and (b) the consultant was in continuous service with the Company on the second anniversary of the grant date. All unvested RSUs would be forfeited on the second anniversary of the grant date.
The initial value of the 100,000 RSUs with market-based vesting conditions granted to the consultant was $288,000, and as of December 31, 2013 the remeasured fair value of those RSUs was $10,080. The 100,000 RSUs were valued using a Monte Carlo Simulation with a 2 year life (based on the grant date), 75%-85% volatility and risk free interest rates of 0.13%-0.36%. During March 2014, the Company terminated its agreement with a consultant that provided for the grant of 100,000 RSUs that had vesting criteria based on the satisfaction of certain market-based conditions subject to the consultant’s continued service, among other things. Upon termination of the agreement, all 100,000 RSUs were forfeited and deemed reconveyed to the Company.
In June 2013, the Company granted an aggregate of 34,325 RSUs to its non-employee directors, valued at $271,854. The RSUs vest in full 13 months after the date of grant subject to the director’s continued service, but the issuance and delivery of these shares are deferred until the director resigns. In September and October 2013, two directors resigned and forfeited all such RSUs.
In October 2013, the Company issued 8,947 RSUs to a former director for his service to the Company as a director, valued at $39,814. The RSUs were to vest in full 13 months after the date of grant subject to the director’s continued service, but the issuance and delivery of these shares are deferred until the director resigns. All such RSUs were forfeited upon the director’s resignation in September 2014.
In November 2013, the Company granted an aggregate of 10,418 RSUs to certain employees, valued at $42,498. The RSUs will vest in equal annual installments over a three-year period.
Grants During the Year Ended December 31, 2014
During the year ended December 31, 2014, the Company granted an aggregate of 26,492 RSUs to its non-employee directors valued at $200,015. These RSUs vest in equal quarterly installments over a one year period subject to the director’s continued service, but the issuance and delivery of these shares are deferred until the director resigns.
A summary of the Company’s RSU activity and related information for the year ended December 31, 2014 is as follows:
		Number of RSUs				Weighted Average Grant Date Fair Value
RSUs unvested - January 1, 2014			1,389,960			$	3.19
RSUs granted			26,492			$	7.55
RSUs vested			(30,690	)		$	7.41
RSUs cancelled/forfeit			(108,947	)		$	3.01
RSUs unvested at December 31, 2014			1,276,815			$	3.2
As of December 31, 2014, the total unrecognized compensation expense related to unvested RSUs was approximately $1,923,000 which is expected to be recognized over a weighted-average period of 1.32 years, based on estimated vesting schedules. The stock-based compensation for RSU’s was $1,332,176 and $822,137 during the years ended December 31, 2014 and 2013, respectively.
Warrants
From time to time, the Company issues warrants to purchase shares of the Company’s common stock to investors, note holders, underwriters and to non-employees for services rendered or to be rendered in the future.
Issuances During the Year Ended December 31, 2013
In February 2013, the Company issued a warrant to purchase 30,000 shares of the Company’s common stock to a consultant with an exercise price of $5.25 per share. The warrants expire three years following the issuance date, and vest as follows: 10,000 shares vested immediately upon execution of the consulting agreement, and the remaining shares vested in 4,000 share installments on each of the five monthly anniversaries of the date of the consulting agreement, provided the consultant continued to provide services to the Company as of the applicable vesting dates.
In July 2013, the Company issued a warrant to purchase 60,000 shares of the Company’s common stock to a consultant with an exercise price of $8.50 per share, in consideration for services to be provided over a six month term. The warrants expire five years following the issuance date, vested immediately, are non-forfeitable, and became exercisable in January 2014. The Company recorded an initial stock-based prepaid consulting expense for the fair value of the warrants totaling $319,786, which was being amortized over the length of the consulting service term.
Issuances During the Year Ended December 31, 2014
The Company did not issue any warrants during the year ended December 31, 2014.
A summary of warrant activity during the year ended December 31, 2014 is as follows:
		Number of Shares Subject to Warrants Outstanding				Weighted Avg.
						Exercise Price
Warrants outstanding - January 1, 2014			821,050			$	5.94
Granted			-			$	-
Exercised			(130,106	)		$	5.28
Expired			-			$	-
Warrants outstanding and exercisable - December 31, 2014			690,944			$	6.05
Weighted average remaining contractual life of the outstanding warrants in years - December 31, 2014			0.86
The fair value of each warrant is estimated on the date of grant using the Black-Scholes-Merton option pricing model. The table below illustrates the fair value per share determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing the warrants issued to consultants:
		Year Ended
		31-Dec-13
Weighted-average fair value of warrants granted		$	5.12
Expected terms (in years)			2.6-5
Expected volatility			85%-346%
Risk-free interest rate			0.32%-1.31%
Dividend yield			-
A list of the warrants outstanding as of December 31, 2014 is included in the following table:
		Warrants Outstanding												Warrants Exercisable
						Warrants				Exercise				Warrants				Expiration
Warrant Series		Issue Date				Outstanding				Price				Exercisable				Date
Warrants issued to a former major shareholder			4/25/12				48,262			$	5.93				48,262				4/25/15
Warrants issued in April 2012 private placement			4/25/12				496,537			$	5.93				496,537				4/25/15
Underwriter Warrants			2/7/13				56,145			$	5.25				56,145				2/7/18
Warrants issued to investor relations consultant			2/28/13				30,000			$	5.25				30,000				2/28/16
Warrants issued to investor relations consultant			7/19/13				60,000			$	8.5				60,000				7/19/18
							690,944			$	6.05				690,944
The stock-based compensation for warrants issued was $26,649 and $468,777 during the years ended December 31, 2014 and 2013, respectively.
The Company recorded stock-based compensation (including the amortization of stock-based prepaid consulting fees, issuance of common stock for services and accrual for stock-based compensation) related to equity instruments granted to employees, directors and consultants as follows:
		For the				For the
		Year Ended				Year Ended
		31-Dec-14				31-Dec-13
Employees - selling and marketing		$	79,278			$	8,298
Employees - general and administrative			2,095,254				1,512,448
Employees - research and development			-				156,568
Directors - general and administrative			146,093				399,986
Consultants - selling and marketing			88,406				-
Consultants - general and administrative			146,799				843,301
Consultants - research and development			8,789				214,372
Total		$	2,564,619			$	3,134,973

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 12. INCOME TAXES
	The Company is subject to taxation in the United States and California. The provision for income taxes for the years ended December 31, 2014 and 2013 are summarized below:
		31-Dec-14			31-Dec-13
	Current:
	Federal	$	-		$	-
	State		2,800			-
	Total current	$	2,800		$	-
	Deferred:
	Federal	$	11,082,459		$	8,075,342
	State		3,100,627			2,233,726
	Change in valuation allowance		(14,183,086	)		(10,309,068	)
	Total deferred		-			-
	Income tax provision (benefit)	$	2,800		$	-
	Income taxes for the years ended December 31, 2014 and 2013, are recorded in the general and administrative expenses line item in the accompanying consolidated statements of operations.
	A reconciliation of income taxes computed by applying the statutory U.S. income tax rate to the Company’s loss before income taxes to the income tax provision is as follows:
		31-Dec-14			31-Dec-13
	U.S. federal statutory tax rate		35	%		35	%
	Benefit of lower tax brackets		(1.00	)%		(1.00	)%
	State tax benefit, net		(0.03	)%		0	%
	Research and development credits		0	%		0.43	%
	Employee stock based compensation		(1.03	)%		(4.72	)%
	Loss on debt conversion		0	%		0	%
	Other		(0.21	)%		(0.08	)%
	Valuation allowance		(32.76	)%		(29.63	)%
	Effective income tax rate		(0.03	)%		0	%
	Deferred tax assets and liabilities reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows:
		31-Dec-14			31-Dec-13
	Deferred tax assets (liabilities):
	NOL’s	$	10,922,914		$	7,364,058
	Depreciation and amortization		(6,787	)		(340	)
	Other		64,806			129,191
	Research & development credits		555,945			563,485
	Deferred stock compensation		2,646,208			2,252,674
	Unrealized gain or loss on investments		-			-
	Total deferred tax assets		14,183,086			10,309,068
	Valuation allowance		(14,183,086	)		(10,309,068	)
	Net deferred tax assets	$	-		$	-
	Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by approximately $3,900,000 and $3,000,000 in 2014 and 2013, respectively.
	As of December 31, 2014, the Company had net operating loss carryforwards for federal income tax purposes of approximately $27,800,000 which expire beginning in the year 2027 and federal research and development tax credits of approximately $350,000 which expire beginning in the year 2026. As of December 31, 2014, the Company had net operating loss carryforwards for state income tax purposes of approximately $24,600,000 which expire beginning in the year 2017 and state research and development tax credits of approximately $300,00 which do not expire.
	The deferred tax asset at December 31, 2014 does not include approximately $30,000 and $30,000 of excess tax benefits from employee stock option exercises and RSU vests that are a component of the federal and California net operating loss carryover, respectively. The Company’s stockholders’ equity balance will be increased if and when such excess tax benefits are ultimately realized.
	Utilization of the net operating losses may be subject to substantial annual limitation due to federal and state ownership change limitations provided by the Internal Revenue Code and similar state provisions. Such annual limitations could result in the expiration of the net operating losses ad credits before their utilization. The Company has not performed an analysis to determine the limitation of the net operating loss and research development credit carryforwards.
	The Company did not have any unrecognized tax benefits of as of December 31, 2014 and 2013, all of which is offset by a full valuation allowance. These unrecognized tax benefits, if recognized, would not affect the effective tax rate.

Employee_Savings_Plan

Employee Savings Plan	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Employee Savings Plan	NOTE 13. EMPLOYEE SAVINGS PLAN
	The Company has established an employee savings plan pursuant to Section 401(k) of the Internal Revenue Code, effective January 1, 2014. The plan allows participating employees to deposit into tax deferred investment accounts up to 100% of their salary, subject to annual limits. The Company makes contributions to the plan in an amount not less than 3% of the participants’ annual cash compensation, subject to annual limits. The Company contributed approximately $56,000 to the plan during the year ended December 31, 2014.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 14. COMMITMENTS AND CONTINGENCIES
	Capital Leases
	The Company leases equipment under capital leases with an interest rate of 4.25% per annum. At December 31, 2014, future payments under the Company’s capital leases were as follows:
	Year ending December 31,
	2015	$	25,477
	2016		19,321
	Total minimum lease payments		44,798
	Less amount representing interest		(1,718	)
	Present value of future minimum lease payments		43,080
	Less current portion		(24,112	)
	Capital lease obligations, net of current portion	$	18,968
	The value of the equipment under capital leases as of December 31, 2014 was $52,687, with related accumulated depreciation of $8,656.
	Operating Leases
	In June 2014, the Company entered into a lease agreement for 7,565 square feet of office space that commenced on September 1, 2014 and continues until October 31, 2018. Monthly rent began on September 1, 2014 in the amount of $20,426, with a 3% increase in the base rent amount on an annual basis. The lease agreement allows for the monthly rent amount to be abated for two months at various times during the lease agreement.
	In April 2013, the Company entered into a lease agreement for 3,784 square feet of office space that commenced on May 1, 2013 and continues until September 30, 2016. Monthly rent began on May 1, 2013 in the amount of $10,406, with a 3% increase in the base rent amount on an annual basis. The lease agreement allows for the monthly rent amount to be abated for five months at various times during the lease agreement. The Company entered into a sublease agreement in February 2015 to sublet 3,874 square feet of its previously occupied offices through the remaining term of the lease.
	In January 2010, PC entered into a lease agreement for 3,137 square feet of office and laboratory space that commenced on January 1, 2010 and continues until December 31, 2015. Monthly rent began on January 1, 2010 in the amount of $3,594.
	Rent expense for the years ended December 31, 2014 and 2013 was $306,465 and $103,191, respectively. The following represents future annual minimum lease payments, including lease payments related to lease agreements entered into in January and February 2015 (see Note 16), and net of expected sublease income, as of December 31, 2014:
	2015	$	492,503
	2016		468,997
	2017		481,443
	2018		495,938
	2019		257,039
	Thereafter		478,473
	Total	$	2,674,393
	Legal
	In the ordinary course of business, the Company may face various claims brought by third parties and the Company may, from time to time, make claims or take legal actions to assert the Company’s rights, including intellectual property disputes, contractual disputes and other commercial disputes. Any of these claims could subject the Company to litigation. Management believes the outcomes of currently pending claims are not likely to have a material effect on the Company’s consolidated financial position and results of operations.
	Indemnities
	In addition to the indemnification provisions contained in the Company’s charter documents, the Company generally enters into separate indemnification agreements with each of the Company’s directors and officers. These agreements require the Company, among other things, to indemnify the director or officer against specified expenses and liabilities, such as attorneys’ fees, judgments, fines and settlements, paid by the individual in connection with any action, suit or proceeding arising out of the individual’s status or service as the Company’s director or officer, other than liabilities arising from willful misconduct or conduct that is knowingly fraudulent or deliberately dishonest, and to advance expenses incurred by the individual in connection with any proceeding against the individual with respect to which the individual may be entitled to indemnification by the Company. The Company also indemnifies its lessors in connection with its facility leases for certain claims arising from the use of the facilities. These indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not been obligated nor incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities in the accompanying consolidated balance sheets.
	Urigen License
	On October 24, 2014, (the “Urigen Effective Date”), the Company entered into a license agreement (the “Urigen License”) with Urigen Pharmaceuticals, Inc. (“Urigen”), pursuant to which Urigen granted to the Company a license under certain U.S. patents and patent applications to develop and sell in the U.S. Urigen’s URG101 product (“HLA”), a heparin and alkalinized lidocaine compounded formulation, for the prevention or treatment of disorders of the lower urinary tract. Such license is non-exclusive; provided that, between April 24, 2015 and October 24, 2015, the Company will have the right, at its option, to convert such non-exclusive license to an exclusive license for the remaining term of the Urigen License, subject only to certain specified existing sublicenses (the “Existing Sublicenses”).
	As consideration for the license granted under the Urigen License, the Company agreed to pay Urigen annual tiered royalties based on sales of HLA, subject to certain minimum annual royalty payments. The annual tiered royalties consist of the greater of (i) $0.50 per dose, and (ii) 15% - 20% of its net sales of HLA, with the royalty amount within such range depending on the Company’s aggregate sales of HLA during the period to which the royalty payment applies. The minimum annual royalty payment consists of (a) for the 2015 calendar year, the greater of (i) 110% of the aggregate royalties paid to Urigen under the Existing Sublicenses during the preceding 12 months, on a prorated basis, and (ii) $800,000, less the aggregate royalties paid to Urigen under the Existing Sublicenses during the 2015 calendar year, and (b) for each calendar year thereafter, 110% of the aggregate amount owed by the Company to Urigen under the Urigen License during the prior calendar year. The Company is obligated to pay such royalties beginning with its first commercial sale of HLA and continuing until the expiration of the patents subject to the license granted under the Urigen License. The Company has also agreed to use commercially reasonable efforts to develop and commercialize HLA according to the terms of a diligence plan agreed to by the parties, which efforts will include, without limitation, the Company’s investment of $2 million in commercialization efforts of HLA, which investment and timeline can be adjusted dependent on market circumstances, and is expected to be incurred over 18-24 months following the Urigen Effective Date.
	Subject to certain conditions and each party’s right to terminate the Urigen License earlier under certain circumstances, the Urigen License will continue in effect until the expiration of the Company’s royalty obligations under the Urigen License. The Urigen License terminates upon the first commercial sale of HLA by Urigen, its affiliates, or a third party after the U.S. Food and Drug Administration (the “FDA”) grants Urigen approval to market HLA in the U.S., if market approval is granted. The Company shall have the option, at its discretion, to become a non-exclusive distributor of HLA following the FDA granting Urigen such market approval. No royalty amounts have been paid or accrued under the Urigen License during the year ended December 31, 2014.
	PCCA License Agreement
	On August 30, 2012, the Company entered into a license agreement with Professional Compounding Centers of America (“PCCA”), pursuant to which PCCA has granted to the Company and its affiliates certain exclusive rights under PCCA’s proprietary formulations, other technologies and data, and the Company has agreed to pay to PCCA certain royalties on net sales relating to the sale of certain potential future FDA-approved products that the Company may produce, which royalties will range from 4.5% to 9% for each such product, subject to certain minimum royalty payments. PCCA may terminate the license agreement if the Company fails to commence efforts to research and develop any such products within certain time periods, as set forth in the license agreement. No royalty amounts have been paid or accrued under this agreement during the years ended December 31, 2014 or 2013.
	PCCA Strategic Alliance Agreement
	On February 18, 2013, the Company entered into a strategic alliance agreement with PCCA. Under this agreement, PCCA has agreed that, during the term of the agreement, it will not introduce any of PCCA’s members or customers meeting certain criteria (the “Member/Customers”) to any third party whereby such third party licenses or otherwise acquires the intellectual property rights of such Member/Customer, without first presenting such an opportunity to the Company. PCCA may, but is not required to, present such opportunities to the Company, use reasonable efforts to facilitate an introductory meeting between the Member/Customer and the Company, and to further provide certain key technical assistance with respect to any potential development project the Company may pursue associated with the Member/Customer’s intellectual property rights. In the event the Company and a Member/Customer introduced to the Company by PCCA enter into a commercial agreement for the license or acquisition of the intellectual property rights owned by the Member/Customer, PCCA will be entitled to receive certain cash fees up to an aggregate of $100,000, as well as a commission based on net sales, if any, generated by the Company as a result of the acquired intellectual property rights. The agreement has a term of one year and is automatically extended for successive one year periods unless either party gives the other written notice of non-renewal. This agreement automatically renewed for a one-year term on February 18, 2014 and 2015. No royalty amounts have been paid or accrued under this agreement during the years ended December 31, 2014 or 2013.
	Asset Purchase Agreements
	The Company has acquired intellectual property rights related to certain proprietary innovations from certain inventors (the “Inventors”) through multiple asset purchase agreements. The asset purchase agreements provide that the Inventors will cooperate with the Company in obtaining patent protection for the acquired intellectual property and that the Company will use commercially reasonable efforts to research, develop and commercialize a product based on the acquired intellectual property. In addition, the Company has acquired a right of first refusal on additional intellectual property and drug development opportunities presented by these Inventors during the term of the respective agreements, which remains in effect until expiration of all payment obligations thereunder.
	In consideration for the acquisition of the intellectual property rights, the Company is obligated to make payments to the Inventors based on the completion of certain milestones, generally consisting of: (1) a payment payable within 30 days after the issuance of the first patent in the United States arising from the acquired intellectual property (if any); (2) a payment payable within 30 days after the Company files the first investigational new drug application (“IND”) with the U.S. Food and Drug Administration (“FDA”) for the first product arising from the acquired intellectual property (if any); (3) for certain of the Inventors, a payment payable within 30 days after the Company files the first New Drug application with the FDA for the first product arising from the acquired intellectual property (if any); and (4) certain royalty payments based on the net receipts received by the Company in connection with the sale or licensing of any product based on the acquired intellectual property (if any), after deducting (among other things) the Company’s development costs associated with such product. If, following five years after the date of the applicable asset purchase agreement, the Company either (a) for certain of the Inventors, has not filed an IND or, for the remaining Inventors, has not initiated a study where data is derived, or (b) has failed to generate royalty payments to the Inventors for any product based on the acquired intellectual property, the Inventors may terminate the applicable asset purchase agreement and request that the Company re-assign the acquired technology to the Inventors. No royalty amounts have been paid or accrued under these agreements for the years ended December 31, 2014 or 2013.
	Novel Drug and Eye Care Northwest Asset Purchase Agreement – Related Party
	On August 8, 2013, the Company acquired intellectual property rights related to certain proprietary innovations from the compounding pharmacy operations of Novel Drug Solutions, LLC (“NDS”) and from Eye Care Northwest, Inc. (together referred to as the “Sellers”) pursuant to an asset purchase agreement (as amended, the “ECN APA”). As part of this acquisition, the Company acquired intellectual property rights that include a provisional patent application related to injectable ophthalmological compositions having anti-bacterial and anti-inflammatory properties for the prevention of post-ophthalmic surgery complications. In addition, under the ECN APA, the Company has a right of first refusal on any of the Sellers’ additional intellectual property and drug development opportunities during the term of the agreement, which remains in effect until the expiration of all payment obligations thereunder. The ECN APA provides that the Sellers will cooperate with the Company in obtaining patent protection for the acquired intellectual property, among other things, and that the Company will use commercially reasonable efforts to research, develop and commercialize a product based on the acquired intellectual property.
	In consideration for the acquisition, the Company is obligated to make the following payments to the Sellers: (1) a payment payable within 30 days after the issuance of the first patent in the United States arising from the acquired intellectual property (if any); (2) a payment payable within 30 days after the Company files the first IND with the FDA for the first product arising from the acquired intellectual property (if any); (3) a payment payable within 30 days after the Company files the first new drug application with the FDA for the first product arising from the acquired intellectual property (if any); and (4) certain royalty payments based on the net receipts received by the Company in connection with the sale or licensing of any product based on the acquired intellectual property (if any), after deducting (among other things) the Company’s development costs associated with such product. If, following five years of the date of the ECN APA, the Company either has not filed an IND or has failed to generate royalty payments to NDS for any product based on the acquired intellectual property, NDS may terminate the ECN APA and request that the Company re-assign the acquired technology to NDS.
	NDS is owned by the former owners of PC. During the years ended December 31, 2014 and 2013, the Company did not make any payments to NDS or the other Seller, and no amounts were due and payable to NDS or the other Seller at December 31, 2014 and 2013.

Segment_Information

Segment Information	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segment Information	NOTE 15. SEGMENT INFORMATION
	The Company operates the business on the basis of a single reportable segment, which is the business of developing proprietary drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services. The Company’s chief operating decision-maker is the Chief Executive Officer, who evaluates the Company as a single operating segment.
	The Company categorizes revenues by geographic area based on selling location. All operations are currently located in the United States; therefore, total revenues for 2014 and 2013 are attributed to the United States. All long-lived assets at December 31, 2014 are located in the United States.
	The Company sells its compounded formulations to a large number of customers. Less than 10% of the Company’s total pharmacy sales were derived from a single customer for the year ended December 31, 2014.
	The Company receives its active pharmaceutical ingredients from three main suppliers. These suppliers collectively accounted for 84% of drug and chemical purchases during the year ended December 31, 2014.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	NOTE 16. SUBSEQUENT EVENTS
	The Company has performed an evaluation of events occurring subsequent to December 31, 2014 through the filing date of this Annual Report on Form 10-K (the “Annual Report”). Based on its evaluation, nothing other than the events described below needs to be disclosed.
	From January 1, 2015 through the filing date of this Annual Report, the Company issued a total of 12,658 shares of common stock as a result of warrant exercises. The Company received gross cash proceeds of $74,998 for the issuance of such shares upon the exercise on a cash basis to purchase the same number of shares of common stock with an exercise price of $5.925.
	In January 2015, the Company issued 8,521 shares of its common stock in connection with RSUs which had been awarded to a non-employee director and vested, but were not issued until the resignation of the director on January 1, 2015.
	On January 1, 2015, the Company completed the acquisition of all of the outstanding capital stock of Park from the previous owners (the “Park Sellers,” and such transaction, the “Park Acquisition”), pursuant to a Stock Purchase Agreement, dated November 26, 2014, by and among the Company, the Park Sellers, Park and the Seller Representative (as defined therein) (the “Park Purchase Agreement”). Park is a compounding pharmacy accredited by the Pharmacy Compounding Accreditation Board and is located in Irvine, California. On January 1, 2015 (the “Park Closing Date”), in connection with the closing of the Park Acquisition (the “Park Closing”), the Company paid to the Park Sellers an aggregate cash purchase price of $3,000,000, net of fees and expenses, subject to adjustment based on the final calculation of Park’s working capital and certain other financial information, and issued to the Park Sellers 63,525 shares of the Company’s common stock, valued at $500,000 based on the average closing price of the common stock for the 10 trading days preceding the Park Closing. In addition, the Company is obligated to make 12 quarterly cash payments to the Park Sellers collectively of $53,125 each over the three years following the Park Closing, totaling $637,500. The Park Sellers have the option to receive the last six of such quarterly payments, totaling up to an aggregate of $318,750, in the form of 6,749 shares of the Company’s common stock for each such payment.
	In connection with the Park Acquisition, one of the Park Sellers, Dennis Saadeh, entered into an employment agreement with the Company, effective as of January 1, 2015, to act as Senior Director of Corporate Development of Park. In addition, on January 1, 2015, Park and an entity affiliated with and controlled by the Park Sellers entered into a Commercial Lease Agreement, for the lease of certain premises to Park of approximately 4,500 square feet of lab and office space. The monthly rent amount is $9,788 and includes annual increases of approximately 3%.
	In February 2015, the Company entered into a lease agreement for approximately 8,602 square feet of lab, warehouse and office space in Roxbury, New Jersey. The current lease term expires on July 31, 2022. The monthly rent amount is $9,548 and includes annual increases of approximately 3.75%, and the lease allows for the first five months of rent amounts to be abated. This facility is currently undergoing construction and being built to serve as an outsourcing facility and pharmacy.
	In February 2015, the Company appointed Andrew R. Boll’s as its Chief Financial Officer, and entered into an amended and restated employment agreement (the “CFO Employment Agreement”) with Mr. Boll, which amends, restates and supersedes in its entirety Mr. Boll’s prior employment agreement with the Company dated February 1, 2012. The CFO Employment Agreement provides for the following, among other things: (i) a term of three years, (ii) an annual base salary of $200,000; (iii) eligibility to receive an annual cash bonus in an amount equal to at least 20% of his then-current annual base salary and a target of 50% of his then-current annual base salary, with the precise amount to be determined at the discretion of the Company’s Board of Directors; (iv) if Mr. Boll is terminated other than for cause, by death or by disability or if he terminates his employment with the Company for good reason (any such termination, a “Qualifying Termination”), then Mr. Boll will be entitled to receive, subject to the satisfaction of certain conditions, continued payments of his then-current annual base salary for six months following the date of his termination and a lump-sum payment equal to the pro-rated portion of his minimum annual cash bonus for the then-current year; and (v) in the event of a Qualifying Termination of Mr. Boll on or within 12 months following a change of control, Mr. Boll will be entitled to receive, subject to the satisfaction of certain conditions, continued payments of his then-current annual base salary for six months following the date of his termination, a lump-sum payment equal to the pro-rated portion of his minimum annual cash bonus for the then-current year, and immediate vesting of all of his outstanding equity awards as of the date of his termination. In connection with Mr. Boll’s appointment as the Company’s Chief Financial Officer, the Company’s Board of Directors has granted the following equity awards to Mr. Boll, in each case under the Plan: (i) a performance-based restricted stock unit award of up to 157,500 shares of the Company’s common stock, which will vest if the Company achieves and maintains certain stock price vesting targets during the three-year period following the date of grant of the award and subject to Mr. Boll’s continued employment with the Company on the third anniversary of the date of grant, subject to certain exceptions, and (ii) a RSU award of up to 30,000 shares of the Company’s common stock, which will vest on the third anniversary of the date of grant, subject to Mr. Boll’s continued employment with the Company on such date and accelerated vesting of all unvested shares thereunder upon the occurrence of a change in control (as defined in the Plan), and is subject to the Company’s standard form of award agreement for RSUs granted under the Plan.
	In February 2015, the Company appointed John P. Saharek as of the Company’s Chief Commercial Officer, effective as of February 1, 2015, and entered into an employment agreement (the “CCO Employment Agreement”) with Mr. Saharek. The CCO Employment Agreement provides for the following, among other things: (i) a term of three years, (ii) an annual base salary of $220,000; (iii) eligibility to receive an annual cash bonus in an amount equal to a target of 50% of his then-current annual base salary, with the precise amount to be determined at the discretion of the Company’s Board of Directors; (iv) in the event of a Qualifying Termination of Mr. Saharek, Mr. Saharek will be entitled to receive, subject to the satisfaction of certain conditions, continued payments of his then-current annual base salary for six months following the date of his termination; and (v) in the event of a Qualifying Termination of Mr. Saharek on or within 12 months following a change of control, then Mr. Saharek will be entitled to receive, subject to the satisfaction of certain conditions, continued payments of his then-current annual base salary for 12 months following the date of his termination and immediate vesting of all of his outstanding equity awards as of the date of his termination. In connection with Mr. Saharek’s appointment as the Company’s Chief Commercial Officer, the Company’s Board of Directors has granted the following equity awards to Mr. Saharek, in each case under the Plan: (i) a stock option award of up to 90,000 shares of the Company’s common stock, which has a term of 10 years and an exercise price of $7.37, will vest in equal quarterly installments over a three-year period, subject to Mr. Saharek’s continued employment with the Company at the end of such period and accelerated vesting of all unvested shares thereunder upon the occurrence of a change in control (as defined in the Plan), and is subject to the Company’s standard form of award agreement for stock options granted under the Plan, and (ii) a RSU award of up to 30,000 shares of the Company’s common stock, which will vest on the third anniversary of the date of grant, subject to Mr. Saharek’s continued employment with the Company on such date and accelerated vesting of all unvested shares thereunder upon the occurrence of a change in control (as defined in the Plan), and is subject to the Company’s standard form of award agreement for restricted stock units granted under the Plan.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation
	On February 28, 2012, the Company effected a one-for-eight reverse stock split and on February 7, 2013, the Company effected a one-for-five reverse stock split. All share and per share amounts in these consolidated financial statements and notes reflect the effects of these reverse stock splits.
	Imprimis has prepared the accompanying consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.
Business Combinations	Business Combinations
	The Company accounts for business combinations by recognizing the assets acquired, liabilities assumed, contractual contingencies, and contingent consideration at their fair values on the acquisition date. The purchase price allocation process requires management to make significant estimates and assumptions at the acquisition date, especially with respect to intangible assets, estimated contingent consideration payments and pre-acquisition contingencies. Examples of critical estimates in valuing certain of the intangible assets we the Company has acquired or may acquire in the future include but are not limited to:
		●	future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed technologies and patents; and
		●	discount rates utilized in valuation estimates.
	Unanticipated events and circumstances may occur that may affect the accuracy or validity of such assumptions, and estimates compared to actual results. Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date, including changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets, will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have a material effect on the consolidated financial position, statements of operations, or cash flows in the period of the change in the estimate.
Research and Development	Research and Development
	The Company expenses all costs related to research and development as they are incurred. Research and development expenses consist of expenses incurred in performing research and development activities, including salaries and benefits, other overhead expenses, and costs related to clinical trials, contract services and outsourced contracts.
Intellectual Property	Intellectual Property
	The costs of acquiring intellectual property rights to be used in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where the Company has identified an alternative future use for the acquired rights. No costs associated with acquiring intellectual property rights have been capitalized to date, although the Company may begin to capitalize certain costs associated with intellectual property rights beginning in the fiscal year 2015. Costs of maintaining intellectual property rights are expensed as incurred.
Revenue Recognition and Deferred Revenue	Revenue Recognition and Deferred Revenue
	The Company recognizes revenues when all of the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. The Company began generating revenues upon the acquisition of PC in the second quarter of 2014, which include sales of certain of the Company’s proprietary compounded drug formulations and certain non-proprietary formulations.
	Product Revenues
	Determination of criteria (3) and (4) is based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Estimated returns and allowances and other adjustments are provided for in the same period during which the related sales are recorded. The Company will defer any revenue received for a product that has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered and no refund will be required.
	License Revenues
	License arrangements may consist of non-refundable upfront license fees, data transfer fees, research reimbursement payments, exclusive license rights to patented or patent pending compounds, technology access fees, and various performance or sales milestones. These arrangements can be multiple element arrangements.
	Non-refundable fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on the part of the Company, are recognized as revenue when the license term commences and the licensed data, technology, compounded drug preparation and/or other deliverable is delivered. Such deliverables may include physical quantities of compounded drug preparations, design of the compounded drug preparations and structure-activity relationships, the conceptual framework and mechanism of action, and rights to the patents or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable fees if it has continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee and that are separate and independent of the Company’s performance under the other elements of the arrangement. In addition, if the Company’s continued involvement is required, through research and development services that are related to its proprietary know-how and expertise of the delivered technology or can only be performed by the Company, then such non-refundable fees are deferred and recognized over the period of continuing involvement. Guaranteed minimum annual royalties are recognized on a straight-line basis over the applicable term.
Cost of Sales	Cost of Sales
	Cost of sales includes direct and indirect costs to manufacture formulations and other products sold, including active pharmaceutical ingredients, personnel costs, packaging, storage, royalties (see Note 14), shipping and handling costs and the write-off of obsolete inventory.
Income Taxes	Income Taxes
	As part of the process of preparing the Company’s consolidated financial statements, the Company must estimate the actual current tax liabilities and assess temporary differences resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within the balance sheet. The Company must assess the likelihood that the deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, a valuation allowance must be established. To the extent the Company establishes a valuation allowance or increase or decrease this allowance in a period, the impact will be included in income tax expense in the statement of operations.
	The Company accounts for income taxes under the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740, “Income Taxes”, or ASC 740. As of December 31, 2014, there were no unrecognized tax benefits included in the consolidated balance sheet that would, if recognized, affect the effective tax rate. The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties in its consolidated balance sheets at December 31, 2014 and 2013, and has not recognized interest and/or penalties in the consolidated statements of operations for the years ended December 31, 2014 and 2013. The Company is subject to taxation in the United States and California. The Company’s tax years since 2000 are subject to examination by the federal and state tax authorities due to the carryforward of unutilized net operating losses.
Cash and Cash Equivalents	Cash and Cash Equivalents
	Cash equivalents include short-term, highly liquid investments with maturities of three months or less at the time of acquisition.
Concentrations of Credit Risk	Concentrations of Credit Risk
	The Company places its cash with financial institutions deemed by management to be of high credit quality. The Federal Deposit Insurance Corporation (“FDIC”) provides basic deposit coverage with limits up to $250,000 per owner. At December 31, 2014, the Company had approximately $7.7 million in cash deposits in excess of FDIC limits.
Accounts Receivable	Accounts Receivable
	The balance in accounts receivable consists of revenue amounts the Company has invoiced and recognized, but for which payment has not been received. Accounts receivable are presented net of an allowance for doubtful accounts in the amount of $3,957 as of December 31, 2014.
Inventories	Inventories
	Inventories are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. The Company evaluates the carrying value of inventories on a regular basis, based on the price expected to be obtained for products in their respective markets compared with historical cost. Write-downs of inventories are considered to be permanent reductions in the cost basis of inventories.
	The Company also regularly evaluates its inventories for excess quantities and obsolescence (expiration), taking into account such factors as historical and anticipated future sales or use in production compared to quantities on hand and the remaining shelf life of products and active pharmaceutical ingredients on hand. The Company establishes reserves for excess and obsolete inventories as required based on its analyses.
Furniture and Equipment	Furniture and Equipment
	Furniture and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization is calculated using the straight-line method over the estimated useful life of the asset. Leasehold improvements and capital lease equipment are amortized over the estimated useful life or remaining lease term, whichever is shorter. Computer software and hardware and furniture and equipment are depreciated over three to five years.
Goodwill and Intangible Assets	Goodwill and Intangible Assets
	The Company reviews its goodwill and indefinite-lived intangible assets for impairment as of January 1 of each year and when an event or a change in circumstances indicates the fair value of a reporting unit may be below its carrying amount. Events or changes in circumstances considered as impairment indicators include but are not limited to the following:
		●	significant underperformance of the Company’s business relative to expected operating results;
		●	significant adverse economic and industry trends;
		●	significant decline in the Company’s market capitalization for an extended period of time relative to net book value; and
		●	expectations that a reporting unit will be sold or otherwise disposed.
	The goodwill impairment test consists of a two-step process as follows:
	Step 1. The Company compares the fair value of each reporting unit to its carrying amount, including the existing goodwill. The fair value of each reporting unit is determined using a discounted cash flow valuation analysis. The carrying value of each reporting unit is determined by specifically identifying and allocating the assets and liabilities to each reporting unit based on headcount, relative revenues, or other methods as deemed appropriate by management. If the carrying amount of a reporting unit exceeds its fair value, an indication exists that the reporting unit’s goodwill may be impaired and the Company then performs the second step of the impairment test. If the fair value of a reporting unit exceeds its carrying amount, no further analysis is required.
	Step 2. If further analysis is required, the Company compares the implied fair value of the reporting unit’s goodwill, determined by allocating the reporting unit’s fair value to all of its assets and its liabilities in a manner similar to a purchase price allocation, to its carrying amount. If the carrying amount of the reporting unit’s goodwill exceeds its fair value, an impairment loss will be recognized in an amount equal to the excess.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets
	Long-lived assets, such as furniture and equipment and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the consolidated balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposal group classified as held-for-sale would be presented separately in the appropriate asset and liability sections of the consolidated balance sheet, if material.
	During the years ended December 31, 2014 and 2013, the Company did not recognize any impairment of its long-lived assets.
Deferred Rent	Deferred Rent
	The Company accounts for rent expense related to its operating leases by determining total minimum rent payments on the leases over their respective periods and recognizing the rent expense on a straight-line basis. The difference between the actual amount paid and the amount recorded as rent expense in each fiscal year and interim periods within each fiscal year is recorded as an adjustment to deferred rent.
Fair Value Measurements	Fair Value Measurements
	Fair value measurements are determined based on the assumptions that market participants would use in pricing an asset or liability. GAAP establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The established fair value hierarchy prioritizes the use of inputs used in valuation methodologies into the following three levels:
	●	Level 1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure fair value whenever available.
	●	Level 2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
	●	Level 3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entity’s own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level 3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method.
	At December 31, 2014 and 2013, the Company did not have any financial assets or liabilities that are measured on a recurring basis. At December 31, 2014 and 2013, the Company’s financial instruments included cash and cash equivalents, restricted short-term investments, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, customer deposits, and capital leases. The carrying amount of these financial instruments, except for the restricted short-term investments and the capital leases, approximates fair value due to the short-term maturities of these instruments. The Company’s restricted short-term investments are carried at amortized cost, which approximates fair value. Based on borrowing rates currently available to the Company, the carrying values of the capital leases approximate their respective fair values.
Stock-Based Compensation	Stock-Based Compensation
	All stock-based payments to employees, directors and consultants, including grants of stock options, warrants, restricted stock units (“RSUs”) and restricted stock, are recognized in the consolidated financial statements based upon their fair values. The Company uses the Black-Scholes-Merton option pricing model and Monte Carlo Simulation to estimate the fair value of stock-based awards. The estimated fair value is determined at the date of grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates.
	The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the Financial Accounting Standards Board (the “FASB”) guidance. As such, the value of the applicable stock-based compensation is periodically remeasured and income or expense is recognized during the vesting terms of the equity instrument. The measurement date for the estimated fair value of the equity instruments issued is the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the estimated fair value of the equity instrument is primarily recognized over the term of the consulting agreement. In accordance with FASB guidance, an asset acquired in exchange for the issuance of fully vested, nonforfeitable equity instruments should not be presented or classified as an offset to equity on the grantor’s balance sheet once the equity instrument is granted for accounting purposes. Accordingly, the Company records the estimated fair value of nonforfeitable equity instruments issued for future consulting services as prepaid expenses in its consolidated balance sheets.
Basic and Diluted Net Loss per Common Share	Basic and Diluted Net Loss per Common Share
	Basic net loss per common share is computed by dividing net loss attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as stock options and warrants, outstanding during the period.
	Basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Common stock equivalents (using the treasury stock or, “if converted” method) from stock options, RSUs and warrants were 3,024,217 and 3,539,800 at December 31, 2014 and 2013, respectively, and are excluded from the calculation of diluted net loss per share for all periods presented because the effect is anti-dilutive. Common stock equivalents at December 31, 2014 include 27,218 shares of common stock underlying RSUs, awarded to directors that have vested, but the issuance and delivery of these shares are deferred until the director resigns.
	The following table shows the computation of basic and diluted net loss per share of common stock for the years ended December 31, 2014 and 2013:
			For the			For the
			Year Ended			Year Ended
			31-Dec-14			31-Dec-13
	Numerator – net loss		$	(10,118,103	)	$	(7,643,124	)
	Denominator – weighted average number of shares outstanding, basic and diluted			9,132,989			8,656,822
	Net loss per share, basic and diluted		$	(1.11	)	$	(0.88	)
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets, and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management are, among others, allowance for doubtful accounts, realizability of inventories, valuation of deferred taxes, goodwill and intangible assets, recoverability of long-lived assets and goodwill, valuation of contingent acquisition obligations, and valuation of stock-based compensation issued to employees and non-employees. Actual results could differ from those estimates.
Reclassifications	Reclassifications
	Certain prior period items and amounts have been reclassified to conform to the classifications used to prepare the consolidated financial statements for the year ended December 31, 2014. The Company has classified in these financial statements certain expenses as selling and marketing, whereas in prior periods certain of these expenses were included in an expense line item titled selling, general and administrative in the consolidated statements of operations. These reclassifications had no material impact on the Company’s financial position, results of operations, or cash flows as previously reported.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements
	In June 2014, the FASB issued an Accounting Standards Update (“ASU”) No. 2014-10, “Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities”. The amendments in this update remove the definition of a development stage entity from ASC Topic 915, “Development Stage Entities”, thereby removing from GAAP the distinction between development stage entities and other reporting entities. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of operations, cash flows, and stockholder’s equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. These amendments are effective for annual reporting periods beginning after December 15, 2014, with early application of the amendments permitted. The Company’s pharmacy operations commenced on April 1, 2014. This change in the nature of the Company’s operations included the recognition of operating revenues; as a result, the Company is no longer defined as a development stage company for reporting dates beginning April 1, 2014. With the change in the Company’s operations, its revenue recognition and its immediate adoption of ASU No. 2014-10, the Company no longer presents or discloses any information required under ASC Topic 915.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements
	In August 2014, the FASB issued new accounting guidance which defines management’s responsibility to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. This guidance will be effective for annual periods ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. The Company is currently evaluating the new guidance and has not determined the impact this standard may have on its consolidated financial statements.
	In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”). The objective of ASU 2014-19 is to establish a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most of the existing revenue recognition guidance, including industry-specific guidance. The core principle of ASU 2014-09 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In applying the new guidance, an entity will (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the contract’s performance obligations; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 applies to all contracts with customers except those that are within the scope of other topics in the FASB ASC. The new guidance is effective for annual reporting periods, including interim periods within those periods, beginning after December 15, 2016 for public companies. Early adoption is not permitted. The Company is currently evaluating the new guidance and has not determined the impact this standard may have on its consolidated financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of Basic and Diluted Earnings Per Common Share	The following table shows the computation of basic and diluted net loss per share of common stock for the years ended December 31, 2014 and 2013:
		For the			For the
		Year Ended			Year Ended
		31-Dec-14			31-Dec-13
	Numerator – net loss	$	(10,118,103	)	$	(7,643,124	)
	Denominator – weighted average number of shares outstanding, basic and diluted		9,132,989			8,656,822
	Net loss per share, basic and diluted	$	(1.11	)	$	(0.88	)

Acquisition_Pharmacy_Creations1

Acquisition - Pharmacy Creations, LLC (Tables)	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Schedule of Acquisition Date Fair Value of Consideration	The total acquisition date fair value of the consideration transferred and to be transferred is estimated at approximately $1.1 million, as follows:
	Cash payment to the PC Sellers at closing	$	600,000
	Contingent common stock issuance to the PC Sellers		483,156
	Contingent cash consideration to the PC Sellers		31,466
	Total acquisition date fair value	$	1,114,622
Schedule of Estimated Fair Value of Assets Acquired and Liabilities Assumed	The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date.
	Cash and cash equivalents	$	4,982
	Accounts receivable		58,420
	Prepaid expenses and other assets		30,256
	Inventory		213,190
	Property and equipment		44,510
	Intangible assets		659,000
	Total identifiable assets acquired		1,010,358
	Accounts payable and accrued liabilities		120,049
	Other liabilities		107,308
	Total liabilities assumed		227,357
	Total identifiable assets less liabilities assumed		783,001
	Goodwill		331,621
	Net assets acquired	$	1,114,622
Schedule of Result of Operation from Acquisition	The amount of revenues and operating loss of PC included in the Company’s consolidated statement of operations from the acquisition date through the period ended December 31, 2014 are as follows:
	Total revenues	$	1,652,386
	Operating loss	$	(662,969	)
Schedule of Pro Forma Financial Information	The unaudited pro forma results presented include amortization charges for intangible assets and eliminations of intercompany transactions.
		For the			For the
		Year Ended			Year Ended
		31-Dec-14			31-Dec-13
	Total revenues	$	2,282,681		$	2,866,575
	Net loss	$	(10,048,380	)	$	(7,084,014	)
Schedule of Intangible Assets Acquisition	The following table sets forth the components of identified intangible assets associated with the PC acquisition and their estimated useful lives.
		Fair Value			Useful Life
	Customer relationships	$	596,000		10 - 15 years
	Trade name		5,000		5 years
	Non-competition covenant		50,000		4 years
	State pharmacy licenses		8,000		25 years
		$	659,000

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Schedule of Inventories	The composition of inventories as of December 31, 2014 was as follows:
		31-Dec-14
	Raw materials	$	146,300
	Work in progress		97,801
	Finished goods		128,634
	Total inventories	$	372,735

Prepaid_Expenses_and_Other_Cur1

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following:
		31-Dec-14		31-Dec-13
	Prepaid stock-based consulting expenses	$	-	$	26,649
	Prepaid rent		-		16,288
	Prepaid insurance		123,776		39,166
	Other prepaid expenses and deposits		116,625		22,964
	Total prepaid expenses and other current assets	$	240,401	$	105,067

Furniture_and_Equipment_Tables

Furniture and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Schedule of Furniture and Equipment	Prepaid expenses and other current assets consisted of the following:
		31-Dec-14		31-Dec-13
	Prepaid stock-based consulting expenses	$	-	$	26,649
	Prepaid rent		-		16,288
	Prepaid insurance		123,776		39,166
	Other prepaid expenses and deposits		116,625		22,964
	Total prepaid expenses and other current assets	$	240,401	$	105,067

Intangible_Assets_and_Goodwill1

Intangible Assets and Goodwill (Tables)	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	The Company’s intangible assets at December 31, 2014 consisted of the following:
		Amortization
		periods				Accumulated			Net
		(in years)		Cost		amortization			carrying value
	Customer relationships	10-15 years		$	596,000	$	(36,740	)	$	559,260
	Trade name	5 years			5,000		(750	)		4,250
	Non-competition covenant	4 years			50,000		(9,375	)		40,625
	State pharmacy licenses	25 years			8,000		(1,141	)		6,859
				$	659,000	$	(48,006	)	$	610,994
Schedule of Amortization Expenses for Intangible Assets	Amortization expense for intangible assets for the year ended December 31, 2014 was as follows:
		For the
		Year Ended
		31-Dec-14
	Customer relationships	$	36,740
	Trade name		750
	Non-competition covenant		9,375
	State pharmacy licenses		1,141
		$	48,006
Schedule of Estimated Future Amortization Expense	Estimated future amortization expense for the Company’s intangible assets at December 31, 2014 is as follows:
	Years ending December 31,
	2015	$	67,087
	2016		67,087
	2017		67,087
	2018		57,712
	2019		53,837
	Thereafter		298,184
		$	610,994
Schedule of Changes in Carrying Value of Goodwill	The changes in the carrying value of the Company’s goodwill during the year ended December 31, 2014 were as follows:
	Balance at January 1, 2014	$	-
	PC Acquisition		331,621
	Balance at December 31, 2014	$	331,621

Accounts_Payable_and_Accrued_E1

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consisted of the following:
			31-Dec-14			31-Dec-13
	Accounts payable		$	698,806		$	261,924
	Deferred rent			4,975			-
	Building lease liability(1)			73,552			-
	Other accrued expenses			39,000	-2		50,000
	Total accounts payable and accrued expenses			816,333			311,924
	Less: Current portion			(786,675	)		(311,924	)
	Non-current total accounts payable and accrued expenses		$	29,658		$	-
		-1	In September 2014, the Company relocated its primary operations to a 7,565 square foot office facility in San Diego, California. As of December 31, 2014, the Company was marketing its previous office space (3,874 square feet) as a sublease through its remaining lease term. The Company recognized a loss of approximately $117,000 during the year ended December 31, 2014, related to the estimated remaining lease liability, net of expected sublease income. The obligations were discounted based on current prevailing market rates. This loss is included in rent expense for the year ended December 31, 2014 (see Note 14).
		-2	The amount consists of a $39,000 stock-based compensation accrual at December 31, 2014 for stock options to be granted for services performed. The stock-based compensation expense related to restricted common stock issuances and accruals was $39,000 and $143,553 during the years ended December 31, 2014 and 2013, respectively.

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2014
Schedule of Stock Option Plan Activity	A summary of the stock option activity under the Plan for the year ended December 31, 2014 is as follows:
			Number of shares				Weighted Avg. Exercise Price				Weighted Avg. Remaining Contractual Life				Aggregate Intrinsic Value
	Options outstanding - January 1, 2014			1,328,790			$	5.31
	Options granted			245,886			$	6.35
	Options exercised			(307,429	)		$	3.9
	Options cancelled/forfeit			(238,007	)		$	6.68
	Options outstanding - December 31, 2014			1,029,240			$	5.74				6.05			$	2,351,174
	Options exercisable			728,585			$	5.25				4.97			$	2,080,594
	Options vested and expected to vest			999,175			$	5.7				5.98			$	2,319,475
Schedule of Fair Value Assumption	The table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees and directors:
			2014				2013
	Weighted-average fair value of options granted		$	5.22			$	6.04
	Expected terms (in years)			5.81 - 6.91				5.8-7
	Expected volatility			96 - 102%				102 - 123%
	Risk-free interest rate			1.37 - 1.65%				0.86 - 2.05%
	Dividend yield			-				-
	The table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to consultants:
			2014				2013
	Weighted-average fair value of options granted		$	6.15			$	5.63
	Expected terms (in years)			2.5 - 10				2.33 - 10
	Expected volatility			78 - 97%				80 - 366%
	Risk-free interest rate			0.10 - 1.68%				0.30 - 2.45%
	Dividend yield			-				-
Schedule of Shares Outstanding and Exercisable	The following table summarizes information about stock options outstanding and exercisable at December 31, 2014:
					Options Outstanding												Options Exercisable
									Weighted
									Average				Weighted								Weighted
									Remaining				Average								Average
					Number				Contractual				Exercise				Number				Exercise
	Range of Exercise Prices				Outstanding				Life in Years				Price				Exercisable				Price
		$2.40 - $3.20				250,000				4.57			$	2.8				250,000			$	2.8
		$3.60 - $4.51				337,723				4.95			$	4.36				270,015			$	4.42
		$5.49 - $7.71				190,557				8.7			$	6.62				60,110			$	6.26
		$8.06 - $10.75				244,160				7.03			$	8.99				141,660			$	9.01
		$28.00 - $80.00				6,800				5.13			$	40.86				6,800			$	40.86
						1,029,240				6.05			$	5.74				728,585			$	5.25
Market-based Vesting Conditions for Restricted Stock Units Granted	These market-based vesting conditions are further described below:
	Tranche		Number of Shares		Target Share Price
	Tranche 1		19.05% of the shares subject to the Baum Performance Equity Award		$10.00 or greater
	Tranche 2		19.05% of the shares subject to the Baum Performance Equity Award		$15.00 or greater
	Tranche 3		19.05% of the shares subject to the Baum Performance Equity Award		$20.00 or greater
	Tranche 4		19.05% of the shares subject to the Baum Performance Equity Award		$25.00 or greater
	Tranche 5		23.80% of the shares subject to the Baum Performance Equity Award		$30.00 or greater
	These market-based vesting conditions are further described below:
	Tranche		Number of Shares		Target Share Price
	Tranche 1		20,000 shares		$10.00 or greater
	Tranche 2		20,000 shares		$15.00 or greater
	Tranche 3		20,000 shares		$20.00 or greater
	Tranche 4		20,000 shares		$25.00 or greater
	Tranche 5		20,000 shares		$30.00 or greater
Schedule of Restricted Stock Units Activity	A summary of the Company’s RSU activity and related information for the year ended December 31, 2014 is as follows:
			Number of RSUs				Weighted Average Grant Date Fair Value
	RSUs unvested - January 1, 2014			1,389,960			$	3.19
	RSUs granted			26,492			$	7.55
	RSUs vested			(30,690	)		$	7.41
	RSUs cancelled/forfeit			(108,947	)		$	3.01
	RSUs unvested at December 31, 2014			1,276,815			$	3.2
Schedule of Warrants Activity	A summary of warrant activity during the year ended December 31, 2014 is as follows:
			Number of Shares Subject to Warrants Outstanding				Weighted Avg.
							Exercise Price
	Warrants outstanding - January 1, 2014			821,050			$	5.94
	Granted			-			$	-
	Exercised			(130,106	)		$	5.28
	Expired			-			$	-
	Warrants outstanding and exercisable - December 31, 2014			690,944			$	6.05
	Weighted average remaining contractual life of the outstanding warrants in years - December 31, 2014			0.86
Schedule of Warrants Outstanding and Warrants Exercisable	A list of the warrants outstanding as of December 31, 2014 is included in the following table:
			Warrants Outstanding												Warrants Exercisable
							Warrants				Exercise				Warrants				Expiration
	Warrant Series		Issue Date				Outstanding				Price				Exercisable				Date
	Warrants issued to a former major shareholder			4/25/12				48,262			$	5.93				48,262				4/25/15
	Warrants issued in April 2012 private placement			4/25/12				496,537			$	5.93				496,537				4/25/15
	Underwriter Warrants			2/7/13				56,145			$	5.25				56,145				2/7/18
	Warrants issued to investor relations consultant			2/28/13				30,000			$	5.25				30,000				2/28/16
	Warrants issued to investor relations consultant			7/19/13				60,000			$	8.5				60,000				7/19/18
								690,944			$	6.05				690,944
Schedule of Stock Based Compensation Granted to Employees Directors Consultants	The Company recorded stock-based compensation (including the amortization of stock-based prepaid consulting fees, issuance of common stock for services and accrual for stock-based compensation) related to equity instruments granted to employees, directors and consultants as follows:
			For the				For the
			Year Ended				Year Ended
			31-Dec-14				31-Dec-13
	Employees - selling and marketing		$	79,278			$	8,298
	Employees - general and administrative			2,095,254				1,512,448
	Employees - research and development			-				156,568
	Directors - general and administrative			146,093				399,986
	Consultants - selling and marketing			88,406				-
	Consultants - general and administrative			146,799				843,301
	Consultants - research and development			8,789				214,372
	Total		$	2,564,619			$	3,134,973
Warrant [Member]
Schedule of Fair Value Assumption	The fair value of each warrant is estimated on the date of grant using the Black-Scholes-Merton option pricing model. The table below illustrates the fair value per share determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing the warrants issued to consultants:
			Year Ended
			31-Dec-13
	Weighted-average fair value of warrants granted		$	5.12
	Expected terms (in years)			2.6-5
	Expected volatility			85%-346%
	Risk-free interest rate			0.32%-1.31%
	Dividend yield			-

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Provision for Income Taxes	The Company is subject to taxation in the United States and California. The provision for income taxes for the years ended December 31, 2014 and 2013 are summarized below:
		31-Dec-14			31-Dec-13
	Current:
	Federal	$	-		$	-
	State		2,800			-
	Total current	$	2,800		$	-
	Deferred:
	Federal	$	11,082,459		$	8,075,342
	State		3,100,627			2,233,726
	Change in valuation allowance		(14,183,086	)		(10,309,068	)
	Total deferred		-			-
	Income tax provision (benefit)	$	2,800		$	-
Schedule of Income Tax Reconciliation	A reconciliation of income taxes computed by applying the statutory U.S. income tax rate to the Company’s loss before income taxes to the income tax provision is as follows:
		31-Dec-14			31-Dec-13
	U.S. federal statutory tax rate		35	%		35	%
	Benefit of lower tax brackets		(1.00	)%		(1.00	)%
	State tax benefit, net		(0.03	)%		0	%
	Research and development credits		0	%		0.43	%
	Employee stock based compensation		(1.03	)%		(4.72	)%
	Loss on debt conversion		0	%		0	%
	Other		(0.21	)%		(0.08	)%
	Valuation allowance		(32.76	)%		(29.63	)%
	Effective income tax rate		(0.03	)%		0	%
Schedule of Deferred Tax Assets and Liabilities	Deferred tax assets and liabilities reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows:
		31-Dec-14			31-Dec-13
	Deferred tax assets (liabilities):
	NOL’s	$	10,922,914		$	7,364,058
	Depreciation and amortization		(6,787	)		(340	)
	Other		64,806			129,191
	Research & development credits		555,945			563,485
	Deferred stock compensation		2,646,208			2,252,674
	Unrealized gain or loss on investments		-			-
	Total deferred tax assets		14,183,086			10,309,068
	Valuation allowance		(14,183,086	)		(10,309,068	)
	Net deferred tax assets	$	-		$	-

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Schedule of Lease Equipment Under Capital Lease	The Company leases equipment under capital leases with an interest rate of 4.25% per annum. At December 31, 2014, future payments under the Company’s capital leases were as follows:
	Year ending December 31,
	2015	$	25,477
	2016		19,321
	Total minimum lease payments		44,798
	Less amount representing interest		(1,718	)
	Present value of future minimum lease payments		43,080
	Less current portion		(24,112	)
	Capital lease obligations, net of current portion	$	18,968
Schedule of Future Payments Under Leases	2015	$	492,503
	2016		468,997
	2017		481,443
	2018		495,938
	2019		257,039
	Thereafter		478,473
	Total	$	2,674,393

Significant_Accounting_Policie

Significant Accounting Policies (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Deposit coverage limits by FDIC, per owner	$250,000
Cash deposits in excess of FDIC limits	7,700,000
Accounts receivable, net of allowance for doubtful accounts	3,957
Impairment of long-lived assets	$0	$0
Common stock equivalents, dilutive instruments	3,024,217	3,539,800
Number of restricted stock included in common stock equivalents	27,218
Minimum [Member]
furniture and equipment depreciated useful life	3 years
Maximum [Member]
furniture and equipment depreciated useful life	5 years

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Schedule of Basic and Diluted Earnings Per Common Share (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Accounting Policies [Abstract]
Numerator - net loss	($10,118,103)	($7,643,124)
Denominator - weighted average number of shares outstanding, basic and diluted	9,132,989	8,656,822
Net loss per share, basic and diluted	($1.11)	($0.88)

Acquisition_Pharmacy_Creations2

Acquisition - Pharmacy Creations, LLC (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash paid for business acquisition	$636,374
Fair value of liability for estimated acquisition	514,622
Pharmacy Creations, LLC [Member]
Cash paid for business acquisition	600,000
Contingent cash payment	50,000
Expected revenue	3,500,000
Expected revenue date	31-Mar-15
Maximum number of common stock applied for contingent stock payment	215,190
Condition for contingent stock payment	if PC earns revenue of over $7,500,000 during the 12 month period ending March 31, 2016, all 215,190 shares;
	if PC earns revenue of between $3,500,000 and $7,500,000 during the 12 month period ending March 31, 2016, an aggregate of that number of shares of Imprimis common stock equal to the amount that such revenue exceeds $3,500,000 divided by 18.5882, rounded down to the lower whole number (not to exceed 215,190 shares).
Business acquisition, total fair value transferred	1,114,622
Business combination purchase price allocation for good will	331,621
Pharmacy Creations, LLC [Member] | Minimum [Member] | Period Ending March 31, 2016
Expected revenue	3,500,000
Expected revenue date	31-Mar-16
Pharmacy Creations, LLC [Member] | Maximum [Member] | Period Ending March 31, 2016
Expected revenue	$7,500,000
Expected revenue date	31-Mar-16

Acquisition_Pharmacy_Creations3

Acquisition - Pharmacy Creations, Llc - Schedule of Acquisition Date Fair Value of Consideration (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash payment to the PC Sellers at closing	$636,374
Pharmacy Creations, LLC [Member]
Cash payment to the PC Sellers at closing	600,000
Contingent common stock issuance to the PC Sellers	483,156
Contingent cash consideration to the PC Sellers	31,466
Total acquisition date fair value	$1,114,622

Acquisition_Pharmacy_Creations4

Acquisition - Pharmacy Creations, Llc - Schedule of Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Goodwill	$331,621
Pharmacy Creations, LLC [Member]
Cash and cash equivalents	4,982
Accounts receivable	58,420
Prepaid expenses and other assets	30,256
Inventory	213,190
Property and equipment	44,510
Intangible assets	659,000
Total identifiable assets acquired	1,010,358
Accounts payable and accrued liabilities	120,049
Other liabilities	107,308
Total liabilities assumed	227,357
Total identifiable assets less liabilities assumed	783,001
Goodwill	331,621
Net assets acquired	$1,114,622

Acquisition_Pharmacy_Creations5

Acquisition - Pharmacy Creations, Llc - Schedule of Result of Operation from Acquisition (Details) (Pharmacy Creations, LLC [Member], USD $)	12 Months Ended
	Dec. 31, 2014
Pharmacy Creations, LLC [Member]
Total revenues	$1,652,386
Operating loss	($662,969)

Acquisition_Pharmacy_Creations6

Acquisition - Pharmacy Creations, Llc - Schedule of Pro Forma Financial Information (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Business Combinations [Abstract]
Total revenues	$2,282,681	$2,866,575
Net loss	($10,048,380)	($7,084,014)

Acquisition_Pharmacy_Creations7

Acquisition - Pharmacy Creations, Llc - Schedule of Intangible Assets Acquisition (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Fair Value	$659,000
Customer Relationships [Member]
Fair Value	596,000
Customer Relationships [Member] | Minimum [Member]
Useful Life	10 years
Customer Relationships [Member] | Maximum [Member]
Useful Life	15 years
Trade Name [Member]
Fair Value	5,000
Useful Life	5 years
Non-Competition Covenant [Member]
Fair Value	50,000
Useful Life	4 years
State Pharmacy Licenses [Member]
Fair Value	$8,000
Useful Life	25 years

Restricted_ShortTerm_Investmen1

Restricted Short-Term Investment (Details Narrative) (USD $)	Dec. 31, 2014
Restricted Short-term Investment
Certificate of deposit	$150,264

Inventories_Schedule_of_Invent

Inventories - Schedule of Inventories (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Inventory Disclosure [Abstract]
Raw materials	$146,300
Work in progress	97,801
Finished goods	128,634
Total inventories	$372,735

Prepaid_Expenses_and_Other_Cur2

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid stock-based consulting expenses		$26,649
Prepaid rent		16,288
Prepaid insurance	123,776	39,166
Other prepaid expenses and deposits	116,625	22,964
Total prepaid expenses and other current assets	$240,401	$105,067

Furniture_and_Equipment_Detail

Furniture and Equipment (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Abstract]
Depreciation and amortization of furniture and equipment	$37,343	$5,659

Furniture_and_Equipment_Schedu

Furniture and Equipment - Schedule of Furniture and Equipment (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Abstract]
Computer software and hardware	$52,576	$24,536
Furniture and equipment	154,215	10,449
Lab and pharmacy equipment	61,868
Leasehold improvements	20,172
Furniture and equipment, gross	288,831	34,985
Accumulated depreciation and amortization	-45,436	-8,093
Furniture and equipment, Net	$243,395	$26,892

Intangible_Assets_and_Goodwill2

Intangible Assets and Goodwill - Schedule of Intangible Assets (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Cost	659,000
Accumulated amortization	-48,006
Net Carrying value	610,994
Customer Relationships [Member]
Cost	596,000
Accumulated amortization	-36,740
Net Carrying value	559,260
Customer Relationships [Member] | Minimum [Member]
Amortization periods (in years)	10 years
Customer Relationships [Member] | Maximum [Member]
Amortization periods (in years)	15 years
Trade Name [Member]
Amortization periods (in years)	5 years
Cost	5,000
Accumulated amortization	-750
Net Carrying value	4,250
Non-Compete Covenant [Member]
Amortization periods (in years)	4 years
Cost	50,000
Accumulated amortization	-9,375
Net Carrying value	40,625
State Pharmacy Licenses [Member]
Amortization periods (in years)	25 years
Cost	8,000
Accumulated amortization	-1,141
Net Carrying value	6,859

Intangible_Assets_and_Goodwill3

Intangible Assets and Goodwill - Schedule of Amortization Expenses for Intangible Assets (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Amortization of intangible assets	$48,006
Customer Relationships [Member]
Amortization of intangible assets	36,740
Trade Name [Member]
Amortization of intangible assets	750
Non-Competition Covenant [Member]
Amortization of intangible assets	9,375
State Pharmacy Licenses [Member]
Amortization of intangible assets	$1,141

Intangible_Assets_and_Goodwill4

Intangible Assets and Goodwill - Schedule of Estimated Future Amortization Expense (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]
2015	$67,087
2016	67,087
2017	67,087
2018	57,712
2019	53,837
Thereafter	298,184
Intangible assets	$610,994

Intangible_Assets_and_Goodwill5

Intangible Assets and Goodwill - Schedule of Changes in Carrying Value of Goodwill (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill, Beginning
PC Acquisition	331,621
Goodwill, Ending	$331,621

Accounts_Payable_and_Accrued_E2

Accounts Payable and Accrued Expenses (Details Narratvie) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2014	Jun. 30, 2014	Apr. 30, 2013
	sqft		sqft	sqft	sqft
Payables and Accruals [Abstract]
Area of office space			7,565	7,565	3,874
Area of previous office space	3,874
Recognized lease losses related to estimated remaining lease liability	$117,000
Stock based compensation accrual	39,000
Stock-based compensation expense related to restricted common stock issuances and accruals	$39,000	$143,553

Accounts_Payable_and_Accrued_E3

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) (USD $)	Dec. 31, 2014		Dec. 31, 2013
Payables and Accruals [Abstract]
Accounts payable	$698,806		$261,924
Deferred rent	4,975
Building lease liability(1)	73,552	[1]		[1]
Other accrued expenses	39,000	[2]	50,000
Total accounts payable and accrued expenses	816,333		311,924
Less: Current portion	-786,675		-311,924
Non-current total accounts payable and accrued expenses	$29,658
[1]	In September 2014, the Company relocated its primary operations to a 7,565 square foot office facility in San Diego, California. As of December 31, 2014, the Company was marketing its previous office space (3,874 square feet) as a sublease through its remaining lease term. The Company recognized a loss of approximately $117,000 during the year ended December 31, 2014, related to the estimated remaining lease liability, net of expected sublease income. The obligations were discounted based on current prevailing market rates. This loss is included in rent expense for the year ended December 31, 2014.
[2]	The amount consists of a $39,000 stock-based compensation accrual at December 31, 2014 for stock options to be granted for services performed. The stock-based compensation expense related to restricted common stock issuances and accruals was $39,000 and $143,553 during the years ended December 31, 2014 and 2013, respectively.

Debt_Details_Narrative

Debt (Details Narrative) (Pharmacy Creations, LLC [Member], USD $)	Dec. 31, 2014
Pharmacy Creations, LLC [Member]
Line of credits borrowing limit maximum	$75,000
Borrowed term loan	$0

Stockholders_Equity_Details_Na

Stockholders' Equity (Details Narrative) (USD $)

0 Months Ended

2 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

Sep. 27, 2013

2-May-13

Feb. 13, 2013

Mar. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Jul. 31, 2013

Feb. 28, 2013

Apr. 02, 2013

24-May-13

Mar. 31, 2014

Jun. 30, 2013

Oct. 31, 2013

Nov. 30, 2013

Oct. 30, 2014

Apr. 30, 2014

Sep. 30, 2013

Jul. 31, 2012

Feb. 08, 2013

Sep. 30, 2014

Capital stock, shares authorized

95,000,000

Common stock, shares authorized

90,000,000

90,000,000

90,000,000

Number of underwritten public offering common stock shares closed

1,840,000

Common stock price per share

$5.25

$4

Proceeds from public offerings

$8,140,435

Additional shares purchased by underwriters

276,000

Net cash proceeds from the exercise of the over-allotment option

1,316,116

Stock issued during period value issued to underwriters

179,860

179,860

Underwriting agreement description

As contemplated by the underwriting agreement entered into with MDB Capital Group, LLC, the lead underwriter for the Public Offering, at the closing of the Public Offering and the over-allotment exercise, the lead underwriters received warrants (the “Underwriter Warrants”) to purchase up to an aggregate of 179,860 shares, or 8.5% of the number of shares sold in the Public Offering (including 8.5% of shares sold pursuant to the exercise of the over-allotment option). The Underwriter Warrants are exercisable at $5.25 per share (100% of the price to the public of the common stock sold in the Public Offering), commencing on the closing date of the Public Offering and expire five years from the closing date of the Public Offering.

Payment made on cancellation of common stock

191

Payment made on cancellation of common stock, shares

35

Common stock issued for services

139,444

Common stock issued settle cashless exercise provision, shares

1,030

Common stock issued shares

66,439

219

Shares issued upon exercise of stock options, shares

227,216

Shares issued upon exercise of stock options

583,811

Additional shares issued upon exercise of stock options, shares

160,777

Proceeds from issuance of common stock

10,052,832

Exercise of common stock option to purchase of common stock

146,652

Issuance of common stock upon vesting of RSUs net of tax withholding , shares

1,954

Number of common stock held for payroll tax

1,518

Issuance of common stock upon vesting of RSUs net of tax withholding

-13,109

Shares issued upon warrants exercise

47,829

Shares issued upon exercise of warrant

37,867

Warrants and shares issued upon excise of common stock

6,391

Warrants to purchase common stock exercise price per share

$5.92

Proceeds from issuance of warrants

Number of warrants shares issued

41,438

Exercise of warrant to purchase of common stock

123,715

Warrants shares exercise price per share

$5.25

Preferred stock, shares authorized

5,000,000

Preferred stock, par value

$0.00

Preferred stock, shares issued

0

Preferred stock, shares outstanding

0

Stock option exercise price

$7.50

Intrinsic value of stock options exercised

1,161,000

Stock options granted vesting terms

Vesting terms for options granted in fiscal years 2014 and 2013 to employees, directors and consultants typically included one of the following vesting schedules: 25% or 33% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% or 67%, respectively, of the shares subject to the option vest and become exercisable in equal quarterly installments thereafter over two or three years, respectively; quarterly vesting over a three year period; or monthly, quarterly or 100% vesting associated with the provision or completion of services provided under contracts with consultants.

Unrecognized compensation expense related to unvested stock options granted under the Plan

1,571,000

Expense expected to recognize over the weighted-average remaining vesting period

2 years 1 month 6 days

Restricted stock units issued

1,250,000

Restricted stock vest in future

1,050,000

Restricted stock vested immediately

200,000

Granted restricted stock units

450,000

Number of granted restricted stock units unvested agreed to cancel

120,000

Fair value of restricted stock units

189,000

Stock based compensation

2,614,619

3,134,973

Stock based compensation of warrants issued

3,018,068

Stock Options [Member]

Stock based compensation

1,137,634

1,689,756

Warrant [Member]

Fair value assumption of volatility, minimum

85.00%

Fair value assumption of volatility, maximum

346.00%

Fair value assumption of risk free interest rates, minimum

0.32%

Fair value assumption of risk free interest rates, maximum

1.31%

Stock based compensation of warrants issued

26,649

468,777

Warrant [Member]

Warrants expire

3 years

Number of warrants vested immeditely

10,000

Number of shares vested in installments for each five months

4,000

Fair value of warrants

319,786

Warrant [Member]

Warrant issued to purchase number of common stock

60,000

30,000

Warrants exercise price

$8.50

5.25

Monte Carlo Simulation [Member]

Issuance of restricted stock units, shares

100,000

Fair value assumptions, life term

2 years

Fair value assumption of volatility, minimum

75.00%

Fair value assumption of volatility, maximum

85.00%

Fair value assumption of risk free interest rates, minimum

0.13%

Fair value assumption of risk free interest rates, maximum

0.36%

Employees And Directors [Member]

Percentage of forfeiture factor

10.00%

Consultant [Member]

Restricted stock units issued

288,000

10,080

Issuance of restricted stock units, shares

100,000

100,000

100,000

Percentage of restricted stock units vested

50.00%

Percentage of remaining restricted stock units vested

50.00%

Issuance of restricted stock units were forfeited and deemed, shares

100,000

Non-Employee Directors [Member]

Restricted stock units issued

200,015

271,854

Issuance of restricted stock units, shares

26,492

34,325

Former Directors [Member]

Restricted stock units issued

39,814

Issuance of restricted stock units, shares

8,947

Employees [Member]

Restricted stock units issued

42,498

Issuance of restricted stock units, shares

10,418

Restricted Stock Units [Member]

Common stock shares issued for services

27,218

40,000

Common stock issued for services

282,997

Number of future issuances share under the plan

2,366,369

Unrecognized compensation expense related to unvested stock options granted under the Plan

1,923,000

Expense expected to recognize over the weighted-average remaining vesting period

1 year 3 months 26 days

Restricted Stock Units [Member] | Non-Employee Directors [Member]

Restricted stock units vest period

1 year

13 months

Restricted Stock Units [Member] | Former Directors [Member]

Restricted stock units vest period

13 months

Restricted Stock Units [Member] | Employees [Member]

Restricted stock units vest period

3 years

2007 Incentive Stock And Awards Plan [Member]

Maximum number of common stock issuance under the plan

5,000,000

Baum Performance Equity Award [Member]

Restricted stock units issued

189,000

Initial fair value of restricted stock units, shares

450,000

Baum Performance Equity Award [Member] | Monte Carlo Simulation [Member]

Issuance of restricted stock units, shares

450,000

Fair value assumptions, life term

3 years

Fair value assumptions, volatility

75.00%

Fair value assumptions, risk free interest rate

0.64%

Baum Performance Equity Award [Member] | Monte Carlo Simulation One [Member]

Issuance of restricted stock units, shares

600,000

Fair value assumptions, life term

3 years

Fair value assumptions, volatility

75.00%

Fair value assumptions, risk free interest rate

0.30%

Restricted Stock Units One [Member]

Stock based compensation

1,332,176

822,137

Minimum [Member]

Stock option purchase of exercise price

$3.68

Common stock exercise price per share

$3.60

Contractual term of stock options granted

3 years

Target ranging price

$10

Granted restricted stock units per person

600,000

Granted restricted stock units

2,400,000

Minimum [Member] | Warrant [Member]

Fair value assumptions, life term

2 years 7 months 6 days

Maximum [Member]

Stock option purchase of exercise price

$4

Common stock exercise price per share

$6

Contractual term of stock options granted

10 years

Target ranging price

$30

Granted restricted stock units per person

1,250,000

Granted restricted stock units

5,000,000

Maximum [Member] | Warrant [Member]

Fair value assumptions, life term

5 years

Restricted Stock [Member]

Common stock shares issued for services

4,000

2,114

Common stock issued for services

29,160

10,750

Common stock issued shares

6,868

Common stock issued shares value

50,000

Mark Baum [Member]

Number of shares issued for related party vesting of RSUs

40,000

Granted restricted stock units

450,000

Number of granted restricted stock units unvested agreed to cancel

120,000

Fair value of canceled restricted stock units plus incremental cost, shares

450,000

Issuance of restricted stock units, shares

450,000

Mark Baum [Member] | Baum Performance Equity Award [Member]

Restricted stock units issued

3,515,090

Issuance of restricted stock units, shares

600,000

Initial fair value of restricted stock units, shares

200,000

Dr. Robert Kammer [Member] | Restricted Stock [Member]

Common stock shares issued for services

40,000

Common stock issued for services

$282,997

Stockholders_Equity_Schedule_o

Stockholders' Equity - Schedule of Stock Option Plan Activity (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Number of shares, Options exercised	227,216
Number of shares, Outstanding, Ending balance	1,029,240
Weighted Avg. Remaining Contractual Life, Options outstanding	6 years 18 days
Stock Option Plan [Member]
Number of shares, Outstanding, Beginning balance	1,328,790
Number of shares, Options granted	245,886
Number of shares, Options exercised	-307,429
Number of shares, Options cancelled/forfeit	-238,007
Number of shares, Outstanding, Ending balance	1,029,240
Number of shares, Options exercisable	728,585
Number of shares, Options vested and expected to vest	999,175
Weighted Avg. Exercise Price, Outstanding, Beginning balance	5.31
Weighted Avg. Exercise Price, Options granted	6.35
Weighted Avg. Exercise Price, Options exercised	3.9
Weighted Avg. Exercise Price, Options cancelled/forfeit	6.68
Weighted Avg. Exercise Price, Outstanding, Ending balance	5.74
Weighted Avg. Exercise Price, Exercisable Ending Balance	5.25
Weighted Avg. Exercise Price, Vested and expected to vest - end of period	5.7
Weighted Avg. Remaining Contractual Life, Options outstanding	6 years 18 days
Weighted Avg. Remaining Contractual Life, Options exercisable	4 years 11 months 19 days
Weighted Avg. Remaining Contractual Life, Options vested and expected to vest	5 years 11 months 23 days
Aggregate Intrinsic Value, Options outstanding	2,351,174
Aggregate Intrinsic Value, Options exercisable	2,080,594
Aggregate Intrinsic Value, Options vested and expected to vest	2,319,475

Stockholders_Equity_Schedule_o1

Stockholders' Equity - Schedule of Fair Value Assumption (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Warrant [Member]
Weighted-average fair value of options granted		$5.12
Expected volatility, minimum		85.00%
Expected volatility, maximum		346.00%
Risk-free interest rate, minimum		0.32%
Risk-free interest rate, maximum		1.31%
Dividend yield		0.00%
Minimum [Member] | Warrant [Member]
Expected terms (in years)		2 years 7 months 6 days
Maximum [Member] | Warrant [Member]
Expected terms (in years)		5 years
Options Granted To Employees [Member]
Weighted-average fair value of options granted	$5.22	$6.04
Expected volatility, minimum	96.00%	102.00%
Expected volatility, maximum	102.00%	123.00%
Risk-free interest rate, minimum	1.37%	0.86%
Risk-free interest rate, maximum	1.65%	2.05%
Dividend yield	0.00%	0.00%
Options Granted To Employees [Member] | Minimum [Member]
Expected terms (in years)	5 years 9 months 22 days	5 years 9 months 18 days
Options Granted To Employees [Member] | Maximum [Member]
Expected terms (in years)	6 years 10 months 28 days	7 years
Options Granted To Consultants [Member]
Weighted-average fair value of options granted	$6.15	$5.63
Expected volatility, minimum	78.00%	80.00%
Expected volatility, maximum	97.00%	366.00%
Risk-free interest rate, minimum	0.10%	0.30%
Risk-free interest rate, maximum	1.68%	2.45%
Dividend yield	0.00%	0.00%
Options Granted To Consultants [Member] | Minimum [Member]
Expected terms (in years)	2 years 6 months	2 years 3 months 29 days
Options Granted To Consultants [Member] | Maximum [Member]
Expected terms (in years)	10 years	10 years

Stockholders_Equity_Schedule_o2

Stockholders' Equity - Schedule of Shares Outstanding and Exercisable (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Number of Options Outstanding	1,029,240
Weighted Average Remaining Contractual Life in Years	6 years 18 days
Weighted Average Exercise Price	$5.74
Number Exercisable	728,585
Weighted Average Exercisable Exercise Price	$5.25
Range One [Member]
Range of Exercise Prices, minimum	$2.40
Range of Exercise Prices, maximum	$3.20
Number of Options Outstanding	250,000
Weighted Average Remaining Contractual Life in Years	4 years 6 months 26 days
Weighted Average Exercise Price	$2.80
Number Exercisable	250,000
Weighted Average Exercisable Exercise Price	$2.80
Range Two [Member]
Range of Exercise Prices, minimum	$3.60
Range of Exercise Prices, maximum	$4.51
Number of Options Outstanding	337,723
Weighted Average Remaining Contractual Life in Years	4 years 11 months 12 days
Weighted Average Exercise Price	$4.36
Number Exercisable	270,015
Weighted Average Exercisable Exercise Price	$4.42
Range Three [Member]
Range of Exercise Prices, minimum	$5.49
Range of Exercise Prices, maximum	$7.71
Number of Options Outstanding	190,557
Weighted Average Remaining Contractual Life in Years	8 years 8 months 12 days
Weighted Average Exercise Price	$6.62
Number Exercisable	60,110
Weighted Average Exercisable Exercise Price	$6.26
Range Four [Member]
Range of Exercise Prices, minimum	$8.06
Range of Exercise Prices, maximum	$10.75
Number of Options Outstanding	244,160
Weighted Average Remaining Contractual Life in Years	7 years 11 days
Weighted Average Exercise Price	$8.99
Number Exercisable	141,660
Weighted Average Exercisable Exercise Price	$9.01
Range Five [Member]
Range of Exercise Prices, minimum	$28
Range of Exercise Prices, maximum	$80
Number of Options Outstanding	6,800
Weighted Average Remaining Contractual Life in Years	5 years 1 month 17 days
Weighted Average Exercise Price	$40.86
Number Exercisable	6,800
Weighted Average Exercisable Exercise Price	$40.86

Stockholders_Equity_Marketbase

Stockholders' Equity - Market-based Vesting Conditions for Restricted Stock Units Granted (Details)	0 Months Ended
	2-May-13	24-May-13
Tranche 1 CEO [Member]
Percentage of Number of Shares Granted	19.05%
Target Share Price	$10.00 or greater
Tranche 2 CEO [Member]
Percentage of Number of Shares Granted	19.05%
Target Share Price	$15.00 or greater
Tranche 3 CEO [Member]
Percentage of Number of Shares Granted	19.05%
Target Share Price	$20.00 or greater
Tranche 4 CEO [Member]
Percentage of Number of Shares Granted	19.05%
Target Share Price	$25.00 or greater
Tranche 5 CEO [Member]
Percentage of Number of Shares Granted	23.80%
Target Share Price	$30.00 or greater
Consultant Tranche 1 [Member]
Number of Shares		20,000
Target Share Price		$10.00 or greater
Consultant Tranche 2 [Member]
Number of Shares		20,000
Target Share Price		$15.00 or greater
Consultant Tranche 3 [Member]
Number of Shares		20,000
Target Share Price		$20.00 or greater
Consultant Tranche 4 [Member]
Number of Shares		20,000
Target Share Price		$25.00 or greater
Consultant Tranche 5 [Member]
Number of Shares		20,000
Target Share Price		$30.00 or greater

Stockholders_Equity_Schedule_o3

Stockholders' Equity - Schedule of Restricted Stock Units Activity (Details) (Restricted Stock Units [Member], USD $)	12 Months Ended
	Dec. 31, 2014
Restricted Stock Units [Member]
Number of RSUs, Outstanding, Beginning balance	1,389,960
Number of RSUs granted	26,492
Number of RSUs vested	-30,690
Number of RSUs cancelled/forfeit	-108,947
Number of RSUs, Outstanding, Ending balance	1,276,815
Weighted Average Grant Date Fair Value, Beginning balance	$3.19
Weighted Average Grant Date Fair Value, RSUs granted	$7.55
Weighted Average Grant Date Fair Value, RSUs vested	$7.41
Weighted Average Grant Date Fair Value, RSUs cancelled/forfeit	$3.01
Weighted Average Grant Date Fair Value, Ending balance	$3.20

Stockholders_Equity_Schedule_o4

Stockholders' Equity - Schedule of Warrants Activity (Details) (Warrant [Member], USD $)	12 Months Ended
	Dec. 31, 2014
Warrant [Member]
Number of shares, Outstanding, Beginning balance	821,050
Number of Shares Subject to Warrants Outstanding, Granted
Number of Shares Subject to Warrants Outstanding, Exercised	-130,106
Number of Shares Subject to Warrants Outstanding, Expired
Number of shares, Outstanding, Ending balance	690,944
Weighted Average Remaining Contractual Life Of The Outstanding Warrants In Years	10 months 10 days
Weighted Avg. Exercise Price, Outstanding, Beginning balance	$5.94
Weighted Avg. Exercise Price, Granted
Weighted Avg. Exercise Price, Exercised	$5.28
Weighted Avg. Exercise Price, Expired
Weighted Avg. Exercise Price, Outstanding, Ending balance	$6.05

Stockholders_Equity_Schedule_o5

Stockholders' Equity - Schedule of Warrants Outstanding and Warrants Exercisable (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Warrant [Member]
Warrants Outstanding	690,944
Exercise Price	$6.05
Warrants Exercisable	690,944
Warrants Issued To Former Major Shareholder [Member]
Issue Date	25-Apr-12
Warrants Outstanding	48,262
Exercise Price	$5.93
Warrants Exercisable	48,262
Expiration Date	25-Apr-15
Warrants Issued In April 2012 Private Placement [Member]
Issue Date	25-Apr-12
Warrants Outstanding	496,537
Exercise Price	$5.93
Warrants Exercisable	496,537
Expiration Date	25-Apr-15
Underwriter Warrants [Member]
Issue Date	7-Feb-13
Warrants Outstanding	56,145
Exercise Price	$5.25
Warrants Exercisable	56,145
Expiration Date	7-Feb-18
Warrants Issued To Investor Relations Consultant [Member]
Issue Date	28-Feb-13
Warrants Outstanding	30,000
Exercise Price	$5.25
Warrants Exercisable	30,000
Expiration Date	28-Feb-16
Warrants Issued To Investor Relations Consultant [Member]
Issue Date	19-Jul-13
Warrants Outstanding	60,000
Exercise Price	$8.50
Warrants Exercisable	60,000
Expiration Date	19-Jul-18

Stockholders_Equity_Schedule_o6

Stockholders' Equity - Schedule of Stock Based Compensation Granted to Employees Directors Consultants (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Stock based compensation related to equity instruments granted to related parties	$2,564,619	$3,134,973
Employees [Member] | Selling And Marketing [Member]
Stock based compensation related to equity instruments granted to related parties	79,278	8,298
Employees [Member] | General And Administrative [Member]
Stock based compensation related to equity instruments granted to related parties	2,095,254	1,512,448
Employees [Member] | Research And Development [Member]
Stock based compensation related to equity instruments granted to related parties		156,568
Directors [Member] | General And Administrative [Member]
Stock based compensation related to equity instruments granted to related parties	146,093	399,986
Consultant [Member] | Selling And Marketing [Member]
Stock based compensation related to equity instruments granted to related parties	88,406
Consultant [Member] | General And Administrative [Member]
Stock based compensation related to equity instruments granted to related parties	146,799	843,301
Consultant [Member] | Research And Development [Member]
Stock based compensation related to equity instruments granted to related parties	$8,789	$214,372

Income_Taxes_Details_Narrative

Income Taxes (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Deferred tax asset valuation allowance	$3,900,000	$3,000,000
Federal net operating loss carryforwards	27,800,000
Federal net operating loss expiration date	2027
Federal research and development tax credits	350,000
Federal research and development tax credits expiration date	2026
State net operating loss carryforwards	24,600,000
State net operating loss expiration date	2017
State research and development tax credits	30,000
Deferrerd tax asset	30,000
Deferrerd tax asset excess tax benefits	$30,000

Income_Taxes_Schedule_of_Provi

Income Taxes - Schedule of Provision for Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Federal
State	2,800
Total current	2,800
Federal	11,082,459	8,075,342
State	3,100,627	2,233,726
Change in valuation allowance	-14,183,086	-10,309,068
Total deferred
Income tax provision (benefit)	$2,800

Income_Taxes_Schedule_of_Incom

Income Taxes - Schedule of Income Tax Reconciliation (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
U.S. federal statutory tax rate	35.00%	35.00%
Benefit of lower tax brackets	-1.00%	-1.00%
State tax benefit, net	-0.03%	0.00%
Research and development credits	0.00%	0.43%
Employee stock based compensation	-1.03%	-4.72%
Loss on debt conversion	0.00%	0.00%
Other	-0.21%	-0.08%
Valuation allowance	-32.76%	-29.63%
Effective income tax rate	-0.03%	0.00%

Income_Taxes_Schedule_of_Defer

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
NOL's	$10,922,914	$7,364,058
Depreciation and amortization	-6,787	-340
Other	64,806	129,191
Research & development credits	555,945	563,485
Deferred stock compensation	2,646,208	2,252,674
Unrealized gain or loss on investments
Total deferred tax assets	14,183,086	10,309,068
Valuation allowance	-14,183,086	-10,309,068
Net deferred tax assets

Employee_Savings_Plan_Details_

Employee Savings Plan (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Percentage of salary deposits in tax deferred investment account	100.00%
Percentage of contributions made by the company	3.00%
Contributions by the company	$56,000

Commitments_and_Contingencies_1

Commitments and Contingencies (Details Narrative) (USD $)	1 Months Ended		12 Months Ended		1 Months Ended	0 Months Ended
	Jun. 30, 2014	Apr. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Jan. 31, 2010	Oct. 24, 2014	Sep. 30, 2014	Feb. 18, 2013
	sqft	sqft			sqft		sqft
Leases equipment under capital lease with interest rate			4.25%
Equipment under capital leases net			$52,687
Related accumulated depreciation			8,656
Lease agreement for office space (Square feet)	7,565	3,874					7,565
Operating lease Expiry	31-Oct-18	30-Sep-16
Operating lease, monthly rental	20,426	10,406
Operating lease, rent increase percentage	3.00%	3.00%	3.00%
Rent expense			306,465	103,191
Maximum aggregate value of cash fees								100,000
Minimum [Member]
Royalties range percentage			4.50%
Maximum [Member]
Royalties range percentage			9.00%
Pharmacy Creations, LLC [Member]
Lease agreement for office space (Square feet)					3,137
Operating lease Expiry					31-Dec-15
Operating lease, monthly rental					3,594
Urigen Pharmaceuticals, Inc [Member]
License agreement commitments description						The annual tiered royalties consist of the greater of (i) $0.50 per dose, and (ii) 15% - 20% of its net sales of HLA, with the royalty amount within such range depending on the Company’s aggregate sales of HLA during the period to which the royalty payment applies. The minimum annual royalty payment consists of (a) for the 2015 calendar year, the greater of (i) 110% of the aggregate royalties paid to Urigen under the Existing Sublicenses during the preceding 12 months, on a prorated basis, and (ii) $800,000, less the aggregate royalties paid to Urigen under the Existing Sublicenses during the 2015 calendar year, and (b) for each calendar year thereafter, 110% of the aggregate amount owed by the Company to Urigen under the Urigen License during the prior calendar year. The Company is obligated to pay such royalties beginning with its first commercial sale of HLA and continuing until the expiration of the patents subject to the license granted under the Urigen License. The Company has also agreed to use commercially reasonable efforts to develop and commercialize HLA according to the terms of a diligence plan agreed to by the parties, which efforts will include, without limitation, the Company’s investment of $2 million in commercialization efforts of HLA, which investment and timeline can be adjusted dependent on market circumstances, and is expected to be incurred over 18-24 months following the Urigen Effective Date.
Minimum royalties to be paid each calendar year						800,000
Value of product development investment						$2,000,000

Commitments_and_Contingencies_2

Commitments and Contingencies - Schedule of Lease Equipment Under Capital Lease (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]
2015	$25,477
2016	19,321
Total minimum lease payments	44,798
Less amount representing interest	-1,718
Present value of future minimum lease payments	43,080
Less current portion	-24,112
Capital lease obligation, net of current portion	$18,968

Commitments_and_Contingencies_3

Commitments and Contingencies - Schedule of Future Payments Under Leases (Details) (USD $)	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
2015	$492,503
2016	468,997
2017	481,443
2018	495,938
2019	257,039
Thereafter	478,473
Total	$2,674,393

Segment_Information_Details_Na

Segment Information (Details Narrative)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Maximum percentage of sales derived from single customer	10.00%
Percentage of drug and chemical purchases from three main suppliers	84.00%

Subsequent_Events_Details_Narr

Subsequent Events (Details Narrative) (USD $)	1 Months Ended		12 Months Ended		1 Months Ended		0 Months Ended		1 Months Ended
	Jun. 30, 2014	Apr. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Mar. 11, 2015	Jan. 31, 2015	Feb. 28, 2015	Jan. 02, 2015	Feb. 28, 2015
							sqft
Shares issued upon exercise of warrants, shares			47,829
Proceeds from issuance of warrants
Common stock issued shares			9,258,231	8,970,364
Issuance of common stock for each payment			66,439	219
Rent amount			306,465	103,191
Expiration of lease term	31-Oct-18	30-Sep-16
Subsequent Event [Member]
Shares issued upon exercise of warrants, shares					12,658
Proceeds from issuance of warrants					74,998
Warrants shares exercise price per share					$5.92
Stock issued during period resticted common stock issued, shares						8,521
Subsequent Event [Member] | Lease Agreement [Member]
Number of square feets of lab and office							8,602		8,602
Rent amount							9,548
Percentage of annual rent increases							3.75%		3.75%
Expiration of lease term							31-Jul-22
Subsequent Event [Member] | Park Sellers [Member]
Aggregate cash purchase price								3,000,000
Common stock issued shares						63,525
Common stock value based on average closing price								500,000
Quarterly cash payments for acquisition								53,125
Amount of closing price, total								637,500
Aggregated amount of closing price								318,750
Issuance of common stock for each payment								6,749
Number of square feets of lab and office						4,500
Rent amount								9,788
Percentage of annual rent increases						3.00%
Subsequent Event [Member] | Andrew R. Boll's [Member] | RSU [Member]
Stock issued during period resticted common stock issued, shares									30,000
Subsequent Event [Member] | Andrew R. Boll's [Member] | CFO Employment Agreement [Member]
Stock issued during period resticted common stock issued, shares									157,500
Employment agreement term									3 years
Annual base salary									200,000
Percentage of current annual salary							20.00%		20.00%
Percentage of target current annual salary							50.00%		50.00%
Subsequent Event [Member] | John P. Saharek [Member] | RSU [Member]
Stock issued during period resticted common stock issued, shares									30,000
Subsequent Event [Member] | John P. Saharek [Member] | CCO Employment Agreement [Member]
Warrants shares exercise price per share							$7.37		7.37
Stock issued during period resticted common stock issued, shares									90,000
Employment agreement term									3 years
Annual base salary									220,000
Percentage of current annual salary							50.00%		50.00%
Term of stock option									10 years